Анализ сайта epic-crown-2.com
Основное Готовность: 10%
Домен
epic-crown-2.com
Состояние доменного имени
?
Проверяем корректность доменного имени и наличие технических проблем на уровне домена.
Длина домена велика. Но если вы продвигаете запрос, входящий в название домена, то это хорошо.
Домен второго уровня идеален для продвижения.
Ответ сервера
200 Успешный ответ
HTTP-код ответа и цепочка редиректов
?
Код 200 — страница доступна. Коды 3xx — редиректы (цепочки замедляют загрузку и размывают ссылочный вес). Коды 4xx/5xx — ошибки, поисковик не сможет проиндексировать страницу.
Сервер настроен корректно.
Безопасность
Сайт небезопасен
Использование HTTPS и SSL-сертификат
?
HTTPS — обязательный стандарт. Google и Яндекс отдают предпочтение защищённым сайтам. Отсутствие SSL или просроченный сертификат ведут к предупреждениям в браузере и снижению позиций.
На сайте не найден защищенный протокол ssl и сайт не открывается по https!
Включён HSTS (Strict-Transport-Security) — защита от подмены на http.
Поздравляем! Сайт не содержится в реестре РКН.
Кодировка
utf-8
Кодировка символов страницы
?
Стандарт — UTF-8. Неправильная кодировка вызывает нечитаемые символы и мешает поисковику корректно распознать текст страницы.
Указана кодировка на странице utf-8.
Язык
Атрибут lang в HTML-теге
?
Атрибут lang (<html lang="ru">) сообщает поисковикам и браузерам, на каком языке написана страница. Помогает при ранжировании в региональном поиске.
Язык страницы не указан. Рекомендуется явно указать язык документа!
Скорость загрузки
~0,68сек
Время отклика сервера (TTFB)
?
Time To First Byte — время до получения первого байта от сервера. Норма до 200 мс. Медленный отклик ухудшает пользовательский опыт и ранжирование: Яндекс и Google учитывают скорость страниц.
Скорость загрузки сайта 0,68сек оптимальна.
Объем документа
125Кб
Размер HTML-кода страницы
?
Слишком большой HTML замедляет парсинг браузером и сканирование поисковым роботом. Рекомендуется не более 200 Кб.
Объем html-документа 125Кб оптимален.
Структура html-документа корректна.
Ресурсы
Ресурсы: 20
Внешние ресурсы страницы (CSS, JS, изображения)
?
Количество и тип подключённых ресурсов влияют на скорость загрузки. Большое число запросов увеличивает время рендеринга страницы.
Кол-во файлов ресурсов 20 много для одной страницы. Приемлемо до 10. Проведите оптимизацию файлов ресурсов!
Показать полный список ресурсов
| Тип | Название | Значение |
|---|---|---|
| stylesheet | text/css | https://fonts.googleapis.com/css?family=Raleway:800,400,300 |
| stylesheet | text/css | https://fonts.googleapis.com/css?family=Open+Sans+Condensed:300 |
| stylesheet | js/libs/bootstrap/css/bootstrap.min.css | |
| stylesheet | css/style_website_v2.css | |
| stylesheet | js/libs/jquery.bxslider/jquery.bxslider.css | |
| stylesheet | css/colors/violet.css | |
| js | https://www.google.com/recaptcha/api.js?hl=en | |
| js | text/javascript | js/libs/jquery.min.js |
| js | text/javascript | js/libs/bootstrap/js/bootstrap.min.js |
| js | text/javascript | js/libs/jquery.bxslider/plugins/jquery.fitvids.js |
| js | text/javascript | js/libs/jquery.bxslider/jquery.bxslider.min.js |
| js | text/javascript | js/scrollit.js |
| js | text/javascript | js/libs/jquery.appear.js |
| js | text/javascript | js/libs/jquery-countTo.js |
| js | text/javascript | js/libs/jquery.touchSwipe.min.js |
| js | text/javascript | js/main.js |
| js | https://www.googletagmanager.com/gtag/js?id=G-9Q27QS9LSN | |
| js | //platform.twitter.com/widgets.js | |
| js | https://maps.googleapis.com/maps/api/js?key=AIzaSyDApou8O9k0YHipRKMG8iuxYIofxQepjs8 | |
| js | text/javascript | js/markerwithlabel_v2.js |
Серверные заголовки
Кол-во: 15
HTTP-заголовки ответа сервера
?
Заголовки сервера передают браузеру и поисковику служебную информацию: кеширование, безопасность (CSP, HSTS), сжатие (gzip). Правильная настройка ускоряет загрузку и повышает защищённость.
Найдены серверные заголовки 15шт. Подробнее про серверные заголовки.
Показать полный список серверных заголовков
| Ключ | Значение |
|---|---|
| Date | Mon, 24 Aug 2026 00:06:07 GMT |
| Server | Apache |
| Cache-Control | no-store, must-revalidate, no-cache |
| Pragma | no-cache |
| Set-Cookie | PHPSESSID=198f245c8a96e97e406e5d715a7709da; path=/; HttpOnly; Secure; SameSite=Lax; |
| Strict-Transport-Security | max-age=31536000; includeSubDomains; preload |
| Referrer-Policy | strict-origin-when-cross-origin |
| Upgrade | h2 |
| Connection | Upgrade |
| Vary | Accept-Encoding |
| X-Frame-Options | SAMEORIGIN |
| Content-Security-Policy | frame-ancestors 'self'; |
| X-Content-Type-Options | nosniff |
| Content-Security-Policy-Report-Only | default-src 'self'; script-src 'self' https: 'unsafe-inline' 'unsafe-eval'; style-src 'self' https: 'unsafe-inline'; img-src 'self' data: https:; font-src 'self' data: https:; connect-src 'self' https:; frame-ancestors 'self'; object-src 'none'; base-uri 'self'; upgrade-insecure-requests; |
| Transfer-Encoding | chunked |
CMS
Не определена
Система управления сайтом (движок)
?
CMS — это движок, на котором работает сайт (WordPress, 1C-Bitrix, Tilda и др.). Знание CMS помогает понять возможности SEO-оптимизации и подобрать подходящие инструменты. «Не определена» — вероятно, самописный сайт или нестандартная сборка.
CMS не определена. Вероятно, сайт самописный либо движок надёжно скрыт. Это не ошибка.
Веб-сервер
Apache
Программное обеспечение сервера
?
Веб-сервер — это ПО, которое отдаёт страницы посетителям (nginx, Apache, IIS, LiteSpeed и др.). Определяется по серверным заголовкам ответа (Server, X-Powered-By и т.п.). «Не определён» — сервер намеренно скрывает эти заголовки, это нормальная практика безопасности.
Сайт работает на веб-сервере Apache.
Мета-теги Готовность: 34%
Title
EPIC CROWN 2
Заголовок страницы в браузере и поисковой выдаче
?
Title — главный SEO-заголовок страницы. Влияет на CTR в поиске и ранжирование. Оптимальная длина: 50–70 символов. Ключевые слова — ближе к началу.
Необходимо увеличить число символов в title (текущее значение мало: 12, минимум: 25, оптимально: от 40 до 45)
Дублей словоформ в title не найдено.
Description
Equine Polyclonal antibodies Immunotherapy against COVID-19/SARS-CoV2–VOC
Описание страницы в поисковой выдаче (сниппет)
?
Meta Description — текст под заголовком в выдаче. Напрямую на позиции не влияет, но влияет на CTR. Оптимальная длина: 120–160 символов.
Необходимо увеличить число символов в description (текущее значение мало: 73, минимум: 80, оптимально: от 120 до 130)
Keywords
Polyclonal antibodies immunotherapy, Variants of concern, Safe antiviral therapeutic approach, Good
Manufacturing Practice, Fab2, project netboard, absiskey
Список ключевых слов страницы (устаревший тег)
?
Meta Keywords не учитывается Яндексом и Google для ранжирования с 2009–2012 годов. Заполнение не обязательно, но не вредит. Конкурент может использовать содержимое для анализа.
Keywords установлены.
Канонический Url
Указывает поисковику основную версию страницы
?
Canonical (rel=canonical) предотвращает проблему дублей страниц. Должен точно совпадать с URL проверяемой страницы. Неправильный canonical может передать ссылочный вес на другую страницу.
Рекомендуем прописать канонический Url.
Robots
Ошибок нет
Директивы для поисковых роботов на уровне страницы
?
Meta Robots управляет индексацией конкретной страницы: index/noindex — индексировать ли, follow/nofollow — следовать ли по ссылкам. Noindex полностью исключает страницу из поиска.
Meta-тег robots не указан. Страница свободна для индексации.
Адаптивность
width=device-width, initial-scale=1.0
Настройка масштабирования на мобильных устройствах
?
Тег viewport (<meta name="viewport">) сообщает браузеру, как масштабировать страницу на мобильных. Стандарт: width=device-width, initial-scale=1. Отсутствие — признак отсутствия мобильной версии.
Meta-тег viewport со значением-константой width=device-width задаёт ширину страницы в соответствии с размером экрана.
Meta-тег viewport со значением initial-scale=1.0 определяет масштаб 1:1, т.е. «не масштабировать».
Разметка OpenGraph
Не найдено
Мета-теги для красивых превью в соцсетях
?
OpenGraph (og:title, og:description, og:image) управляет тем, как страница выглядит при репосте в социальных сетях и мессенджерах. Отсутствие OG-тегов — невзрачный превью при шеринге.
Разметка OpenGraph не задана. Страница не оптимизирована под социальные сети. Мета-теги с разметкой Og помогают социальным роботам лучше структурировать Ваш сайт.
Все мета-теги
Кол-во: 3
Полный список мета-тегов страницы
?
Таблица всех meta-тегов, включая нестандартные. Позволяет найти опечатки, дубли и лишние теги.
Найдены мета-теги 3шт. Мета-теги не видимы для человека и предназначены для обмена информацией между веб-страницей и поисковыми системами, браузерами и другими веб-службами. С ними роботы 🤖 и устройства ведут себя более ожидаемо.
Показать полный список мета-тегов
| Тип | Название | Значение |
|---|---|---|
| name | description | Equine Polyclonal antibodies Immunotherapy against COVID-19/SARS-CoV2–VOC |
| name | keywords | Polyclonal antibodies immunotherapy, Variants of concern, Safe antiviral therapeutic approach, Good Manufacturing Practice, Fab2, project netboard, absiskey |
| name | viewport | width=device-width, initial-scale=1.0 |
Оптимизация Готовность: 82%
Структура
Ошибок нет
Семантические HTML-элементы страницы
?
Проверяет наличие основных структурных элементов: nav, header, footer, main. Корректная семантическая структура помогает поисковику понять архитектуру страницы.
Структура документа корректна (теги <html> и <body> присутствуют по одному на документ).
Контент
Ошибок нет
Объём и качество текстового содержимого
?
Анализирует объём полезного текста на странице. Слишком мало — страница может считаться малополезной. Слишком много — ухудшается читаемость и восприятие.
Слова из title 3 встречаются в тексте достаточно.
Абзацев с текстом 126 достаточно.
Среднее число слов в абзаце 25 достаточно.
Кол-во знаков контента 42288 на странице оптимально.
Кол-во слов 6308 на странице оптимально.
Заголовки
Ошибок нет
Иерархия заголовков H1–H6
?
H1 должен быть один и содержать ключевой запрос. H2–H6 описывают подразделы. Пропуск уровней (H1 → H3) и несколько H1 — типичные ошибки, снижающие понятность страницы для поисковика.
На странице присутствуют заголовки <h1> 1. Это прекрасно.
На странице присутствуют заголовки <h2> 10. Это хорошо.
На странице присутствуют заголовки <h3> 18.
Тошнота
7,35
Насколько одно слово доминирует в тексте
?
Классическая тошнота = √(частота самого повторяющегося слова). Норма до 7–8: текст воспринимается естественно. Выше — поисковик может счесть страницу переспамленной.
Тошнота превышает норму 5. Измените текст страницы!
Академич. тошнота
52,47%
Насколько текст перенасыщен ключевыми словами
?
Академическая тошнота = (частота слова / общее количество слов) × 100%. Показывает долю конкретного слова в тексте. Норма 5–15%.
Академическая тошнота превышает норму 5-15%. Измените текст страницы!
Семантическое ядро
20
Наиболее часто встречающиеся слова на странице
?
Топ слов по частоте использования. Показывает, какие слова доминируют в тексте с точки зрения поисковика.
Контент страницы содержит осмысленный текст и слова.
Показать список слов
| Слово | Кол-во | Частота |
|---|---|---|
| project | 54 | 0,86% |
| personal | 36 | 0,57% |
| absiskey | 32 | 0,51% |
| european | 22 | 0,35% |
| clinical | 22 | 0,35% |
| assembly | 20 | 0,32% |
| article | 20 | 0,32% |
| general | 19 | 0,30% |
| treatment | 17 | 0,27% |
| objective | 16 | 0,25% |
| belledant | 16 | 0,25% |
| studies | 15 | 0,24% |
| projects | 15 | 0,24% |
| websites | 15 | 0,24% |
| research | 14 | 0,22% |
| antibodies | 13 | 0,21% |
| onclick="gtag | 13 | 0,21% |
| 'event' | 13 | 0,21% |
| 'news' | 13 | 0,21% |
| partners | 12 | 0,19% |
Индексация Готовность: 30%
Индексирование
Ошибок нет
Разрешено ли индексирование страницы
?
Проверяет, не закрыта ли страница от индексации через robots.txt, meta robots или X-Robots-Tag. Страница, закрытая от индексации, не появится в поисковой выдаче.
Анкоров на странице 62 оптимально. Поисковые роботы обязательно проиндексируют сайт.
Robots.txt
Найден корректный robots.txt
Файл управления сканированием сайта роботами
?
Robots.txt указывает поисковым роботам, какие страницы сканировать, а какие — нет. Ошибки в файле могут случайно закрыть важные разделы от индексации.
Robots.txt настроен корректно. Размер файла: 128934 байт. Загружен за: 1сек.
Проверяемая страница не запрещена в robots.txt.
Robots.txt доступен по постоянному адресу
Показать содержимое robots.txt
<!DOCTYPE html>
<html>
<head>
<title>EPIC CROWN 2</title>
<link rel="icon" type="image/png" href="upload/epiccrown2/website/Logo EPIC CROWN 2 - symbol final 2.png" />
<meta name="description" content="Equine Polyclonal antibodies Immunotherapy against COVID-19/SARS-CoV2–VOC" />
<meta name="keywords" content="Polyclonal antibodies immunotherapy, Variants of concern, Safe antiviral therapeutic approach, Good
Manufacturing Practice, Fab2, project netboard, absiskey" />
<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<link href='https://fonts.googleapis.com/css?family=Raleway:800,400,300' rel='stylesheet' type='text/css'>
<link href='https://fonts.googleapis.com/css?family=Open+Sans+Condensed:300' rel='stylesheet' type='text/css'>
<link href="js/libs/bootstrap/css/bootstrap.min.css" rel="stylesheet">
<link href="css/style_website_v2.css" rel="stylesheet">
<link href="js/libs/jquery.bxslider/jquery.bxslider.css" rel="stylesheet">
<link href="css/colors/violet.css" rel="stylesheet">
<!-- HTML5 element support for IE6-8 -->
<!--[if lt IE 9]>
<script type="text/javascript" src="../js/html5shiv.js"></script>
<script type="text/javascript" src="../js/respond.min.js"></script>
<![endif]-->
<script src="https://www.google.com/recaptcha/api.js?hl=en" async defer></script>
<script type="text/javascript" src="js/libs/jquery.min.js"></script>
<script type="text/javascript" src="js/libs/bootstrap/js/bootstrap.min.js"></script>
<script type="text/javascript" src="js/libs/jquery.bxslider/plugins/jquery.fitvids.js"></script>
<script type="text/javascript" src="js/libs/jquery.bxslider/jquery.bxslider.min.js"></script>
<script type="text/javascript" src="js/scrollit.js"></script>
<script type="text/javascript" src="js/libs/jquery.appear.js"></script>
<script type="text/javascript" src="js/libs/jquery-countTo.js"></script>
<script type="text/javascript" src="js/libs/jquery.touchSwipe.min.js"></script>
<script type="text/javascript" src="js/main.js"></script>
<!-- Global site tag (gtag.js) - Google Analytics -->
<script async src="https://www.googletagmanager.com/gtag/js?id=G-9Q27QS9LSN"></script>
<script>
window.dataLayer = window.dataLayer || [];
function gtag(){dataLayer.push(arguments);}
gtag('js', new Date());
gtag('config', 'G-9Q27QS9LSN', { 'anonymize_ip': true, 'cookie_expires': 365 * 24 * 60 * 60 });
</script>
</head>
<body data-spy="scroll" data-target=".vitamib-navbar-scroll" class="version2">
<!-- pop in-->
<div class="modal fade" id="myModal" tabindex="-1" role="dialog" aria-labelledby="myModalLabel" aria-hidden="true" style="text-align:justify;">
<div class="modal-dialog">
<div class="modal-content">
<div class="modal-header">
<button type="button" class="close" data-dismiss="modal" aria-label="Close"><span aria-hidden="true">×</span></button>
<h4 class="modal-title" id="myModalLabel">News 1</h4>
</div>
<div class="modal-body" id="myModalText">
<p>Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed in mollis sem, nec luctus ligula. Duis ullamcorper turpis ac purus pretium lacinia non ut metus. Nunc scelerisque urna mollis neque tristique rutrum. Aenean metus turpis, hendrerit id porta non, viverra ut felis. Etiam ultricies vulputate quam vitae molestie. Mauris a fermentum turpis. Donec leo nisi, porttitor et rhoncus vitae, dictum vitae arcu. Etiam tincidunt accumsan arcu, et pellentesque lorem. Nullam lobortis turpis at scelerisque dapibus. Fusce in cursus lorem. Vestibulum a pretium turpis, ut dapibus dolor. Aenean quis lacus nec nulla interdum sodales. Fusce facilisis viverra condimentum.</p>
</div>
<div class="modal-footer">
<button type="button" class="btn" data-dismiss="modal">Close</button>
</div>
</div>
</div>
</div>
<!-- navbar burger mobile -->
<header class="navbar" role="banner">
<div class="navbar-header">
<button class="navbar-toggle collapsed" type="button" data-toggle="collapse" data-target=".vitamib-navbar-collapse">
<span class="sr-only">Toggle navigation</span>
<span class="icon-bar"></span>
<span class="icon-bar"></span>
<span class="icon-bar"></span>
</button>
</div>
<!-- navbar -->
<nav class="collapse navbar-collapse vitamib-navbar-collapse vitamib-navbar-scroll">
<ul class="nav navbar-nav">
<li> <a href="#header-project" data-scroll-nav="0"> Project </a> </li>
<li> <a href="#video" data-scroll-nav="3"> Videos </a></li>
<li> <a href="#partners" data-scroll-nav="4"> Partners </a></li>
<li> <a href="#graph-chart" data-scroll-nav="5"> Graph - Chart</a></li>
<li> <a href="#news" data-scroll-nav="6"> News </a></li>
<li> <a href="#events" data-scroll-nav="7"> Events </a></li>
<li> <a href="#documents" data-scroll-nav="8"> Documents </a></li>
<li> <a href="#contact" data-scroll-nav="9"> Contact us </a></li>
</ul>
</nav>
<!-- end navbar-->
</header>
<!-- end navbar burger mobile-->
<!-- section project-->
<section id="header-project" data-scroll-index="0">
<div class="container">
<div class="row">
<div class="col-sm-2">
<img style="max-height:160px;" src="upload/epiccrown2/website/Logo EPIC CROWN 2 - symbol final 2.png" class="img-responsive" alt="...">
</div>
<div class="col-sm-10">
<h1><span >EPIC CROWN 2</span> Equine Polyclonal antibodies Immunotherapy against COVID-19/SARS-CoV2–VOC</h1>
</div>
</div>
<!-- carousel-->
<div id="main_area">
<!-- Slider -->
<div class="row">
<div class="col-xs-12" id="slider">
<!-- Top part of the slider -->
<div class="row">
<div class="col-sm-12" id="carousel-bounding-box">
<div class="carousel slide" id="myCarousel">
<!-- Carousel items -->
<div class="carousel-inner">
<!--div class="active item" data-slide-number="0">
<img src="http://placehold.it/1170x550&text=one"></div>-->
<div class="active item" data-slide-number="0" style="background-image:url(upload/epiccrown2/website/newscoverphoto1.jpg)">
<!--<img src="upload/epiccrown2/website/newscoverphoto1.jpg">--></div>
<div class=" item" data-slide-number="1" style="background-image:url(upload/epiccrown2/website/newscoverphoto2.jpeg)">
<!--<img src="upload/epiccrown2/website/newscoverphoto2.jpeg">--></div>
<div class=" item" data-slide-number="2" style="background-image:url(upload/epiccrown2/website/newscoverphoto4.png)">
<!--<img src="upload/epiccrown2/website/newscoverphoto4.png">--></div>
</div><!-- Carousel nav -->
<a class="left carousel-control" href="#myCarousel" role="button" data-slide="prev">
<span class="glyphicon glyphicon-chevron-left"></span>
</a>
<a class="right carousel-control" href="#myCarousel" role="button" data-slide="next">
<span class="glyphicon glyphicon-chevron-right"></span>
</a>
</div>
</div>
<div class="col-sm-12" id="carousel-text"></div>
<div id="slide-content" style="display: none;">
<!--div id="slide-content-0">
<h3>Slider One</h3>
<p>Phasellus ac ultrices justo. Donec in dui viverra, sodales ligula sit amet, iaculis tortor. Aenean dignissim nisl a elementum mattis. Duis venenatis et eros nec laoreet. Fusce eu sodales nulla, euismod eleifend ligula. Sed augue eros, faucibus nec leo id, pulvinar dapibus quam. Cum sociis natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Sed et mi mauris. Duis cursus enim mauris, faucibus vehicula lacus ullamcorper at.</p>
<a href="#" class="btn">Read more</a>
</div-->
<div id="slide-content-0">
<h3>Objectives of the Epic Crown 2 project</h3>
<p>Objective 1: To assess beneficial impacts of this treatment and to optimise the therapeutic indications through European multicentric clinical studies Phase II...</p>
<a href="#" class="btn" data-toggle="modal" data-target="#myModal" data-title="Objectives of the Epic Crown 2 project" data-text='<p><b>Objective 1</b>: To assess beneficial impacts of this treatment and to optimise the therapeutic indications through European multicentric clinical studies Phase II a/b on 16 and 400 patients, respectively.</p><p><b>Objective 2</b>: To analyse the impact of SARS-CoV-2 VOC within clinical batches of polyclonal F(ab’)2 (FBR-002) antibodies by <em>in vitro</em> and <em>in vivo</em> studies.</p><p><b>Objective 3</b>: Prospective clinical and <em>in vivo</em> studies to improve the indications of the treatment.</p><p><b>Objective 4</b>: Preparation of the market uptake to timely access to GMP production to be trialled and strategy definition for the upscale production.</p><p> </p>' onClick="gtag('event','news',{ event_category:'click_news_slider', event_label:'Objectives of the Epic Crown 2 project'})"> View more </a>
</div>
<div id="slide-content-1">
<h3>General Assembly of Epic Crown 2 project</h3>
<p>Very fruitful General Assembly with all partners from the Epic Crown 2 consortium last week, in Attikon University Hospital, Greece.Special thanks to Pr...</p>
<a href="#" class="btn" data-toggle="modal" data-target="#myModal" data-title="General Assembly of Epic Crown 2 project" data-text='<p>Very fruitful General Assembly with all partners from the Epic Crown 2 consortium last week, in Attikon University Hospital, Greece.</p><p>Special thanks to Pr Giamarellos-Bourboulis for hosting all partners for this very important meeting. This helped us a lot to coordinate this Horizon Europe project.</p><p>In a nutshell, great exchanges with european colleagues and partners from the Bernard Nocht Institute (Germany), the Hospital Universitario 12 de Octubre (Spain) , the Institute for Reasearch and Development (France) and the Hellenic Institute for the Study of Sepsis (Greece).</p><br><img class="img-responsive center-block" src="upload/epiccrown2/news/news_7475_epic meeting.jpeg" alt="">' onClick="gtag('event','news',{ event_category:'click_news_slider', event_label:'General Assembly of Epic Crown 2 project'})"> View more </a>
</div>
<div id="slide-content-2">
<h3>Epic Crown 2 project passed review from European Commission</h3>
<p>It is time to celebrate! According to the reviewers from the European Commission, the Epic Crown 2 team has obtained very interesting preclinical research...</p>
<a href="#" class="btn" data-toggle="modal" data-target="#myModal" data-title="Epic Crown 2 project passed review from European Commission" data-text='<p>It is time to celebrate! According to the reviewers from the European Commission, the Epic Crown 2 team has obtained very interesting preclinical research findings demonstrating the promise of polyclonal antibodies to address multiple VoCs. We will keep working hard to achieve great results for the health sector!</p><p><a href="https://www.freepik.com/free-vector/group-medical-staff-carrying-health-related-icons_3226126.htm">Image by rawpixel.com</a> on Freepik</p><br><img class="img-responsive center-block" src="upload/epiccrown2/news/news_7475_group-of-medical-staff.jpg" alt="">' onClick="gtag('event','news',{ event_category:'click_news_slider', event_label:'Epic Crown 2 project passed review from European Commission'})"> View more </a>
</div>
</div>
</div>
</div>
</div><!--/Slider-->
<div class="row hidden-xs" id="slider-thumbs">
<!-- Bottom switcher of slider -->
<ul class="hide-bullets">
<li class="col-sm-2">
<a class="thumbnail" style="display:block;" id="carousel-selector-0">
<div class="item" style="background-image:url(upload/epiccrown2/website/newscoverphoto1.jpg)"></div>
</a>
</li>
<li class="col-sm-2">
<a class="thumbnail" style="display:block;" id="carousel-selector-1">
<div class="item" style="background-image:url(upload/epiccrown2/website/newscoverphoto2.jpeg)"></div>
</a>
</li>
<li class="col-sm-2">
<a class="thumbnail" style="display:block;" id="carousel-selector-2">
<div class="item" style="background-image:url(upload/epiccrown2/website/newscoverphoto4.png)"></div>
</a>
</li>
</ul>
</div>
</div>
</div>
<!-- end carousel-->
</section>
<section id="project">
<!-- block bg-light-->
<div class="bg-light">
<div class="container">
<div class="row">
<div class="col-md-12">
<!--block abstract -->
<div class="abstract row" style="text-align:justify;">
<div class="preview-collapse collapsed" data-toggle="collapse" data-target="#collapseAbstract" aria-expanded="false" aria-controls="collapseAbstract">
<div class="col-lg-3 col-md-4 col-sm-12 col-xs-12">
<svg id="abstract" class="ico" data-name="abstract" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 462.35 419.91"><title>Abstract</title><path class="cls-1" d="M235.7,81.72a8.13,8.13,0,0,0-8.13-8.13,85.2,85.2,0,0,0-85.11,85.11,8.13,8.13,0,0,0,16.26,0,68.93,68.93,0,0,1,68.85-68.85A8.12,8.12,0,0,0,235.7,81.72Z" transform="translate(0 -21.22)"/><path class="cls-1" d="M108.31,158.7A123.39,123.39,0,0,0,134.38,235l0.26,0.32c35.58,49.39,26.74,72.88,26.74,72.92A8.14,8.14,0,0,0,165.29,319a8,8,0,0,0,3.44.76,8.12,8.12,0,0,0,7.36-4.68c1.47-3.12,13.1-32.21-28.69-89.91a8.39,8.39,0,0,0-.59-0.72,107.29,107.29,0,0,1-22.25-65.79,108.32,108.32,0,1,1,194.12,66.15C276.88,282.58,289,312,290.48,315.17A8.05,8.05,0,0,0,301.1,319a8.22,8.22,0,0,0,4.14-10.64c-0.1-.24-9.41-24.2,26.48-73.77a123.44,123.44,0,0,0,25.75-75.86A124.58,124.58,0,0,0,108.31,158.7Z" transform="translate(0 -21.22)"/><path class="cls-1" d="M305.44,351.08v-6.91a20,20,0,0,0-20-20H175.93a20,20,0,0,0-20,20v6.91a20,20,0,0,0,20,20H285.48A20,20,0,0,0,305.44,351.08Zm-133.23,0v-6.91a3.72,3.72,0,0,1,3.71-3.71H285.48a3.72,3.72,0,0,1,3.71,3.71v6.91a3.72,3.72,0,0,1-3.71,3.71H175.93A3.72,3.72,0,0,1,172.21,351.08Z" transform="translate(0 -21.22)"/><path class="cls-1" d="M189.09,383.41a8.13,8.13,0,0,0-8.13,8.13V413a8.14,8.14,0,0,0,4.76,7.4l43.8,20a8.12,8.12,0,0,0,6.84,0l43.93-20.73a8.12,8.12,0,0,0,4.66-7.35V391.55a8.13,8.13,0,0,0-16.26,0v15.57L232.83,424l-35.62-16.26V391.55A8.12,8.12,0,0,0,189.09,383.41Z" transform="translate(0 -21.22)"/><path class="cls-1" d="M422.26,305.58a8.13,8.13,0,0,0-1.71-11.36L365.4,253.56a8.13,8.13,0,1,0-9.65,13.08L410.9,307.3A8.13,8.13,0,0,0,422.26,305.58Z" transform="translate(0 -21.22)"/><path class="cls-1" d="M99.16,77.47a8.13,8.13,0,0,0,9.66-13.09L52.43,22.81A8.13,8.13,0,0,0,42.78,35.9Z" transform="translate(0 -21.22)"/><path class="cls-1" d="M101.72,250.76L42.79,294.22a8.13,8.13,0,0,0,9.66,13.09l58.93-43.46A8.13,8.13,0,0,0,101.72,250.76Z" transform="translate(0 -21.22)"/><path class="cls-1" d="M358.16,61.7a8.13,8.13,0,0,0,9.66,13.09L420.56,35.9a8.13,8.13,0,0,0-9.65-13.08Z" transform="translate(0 -21.22)"/><path class="cls-1" d="M454.22,156.93H392a8.13,8.13,0,0,0,0,16.26h62.17A8.13,8.13,0,0,0,454.22,156.93Z" transform="translate(0 -21.22)"/><path class="cls-1" d="M80.42,165.06a8.13,8.13,0,0,0-8.13-8.13H8.13a8.13,8.13,0,1,0,0,16.26H72.29A8.13,8.13,0,0,0,80.42,165.06Z" transform="translate(0 -21.22)"/></svg>
<h3> Abstract </h3>
</div>
<div class="col-lg-9 col-md-8 col-sm-12 col-xs-12">
<p><p>The highly contagious SARS-CoV-2 virus has generated an unprecedented pandemic with global dramatic public health and socioeconomic consequences need an urgent mitigation. Despite the progression of the global use of efficient vaccines, an increased transmissibility of variants of concern (VOC) is predominantly observed. The reduced sensitivity of VOCs to neutralizing response could become a serious obstacle for efficient vaccination.</p>
</div>
</div>
<div class="collapse col-lg-9 col-md-8 col-lg-offset-3 col-md-offset-4 col-sm-12" id="collapseAbstract">
<p> In the absence of approved specific antiviral therapies for vaccinated-non-responders and the scarce anti-inflammatory therapies, passive immunotherapies with polyclonal immunoglobulins could be considered a part of the solution.</p><p> </p><p>The main objective of EPIC-CROWN-2 is to rapidly assess, in multicentric clinical trials, an EMA-authorized antiviral immunotherapy based on potent and broad equine neutralizing anti-SARS-CoV-2 polyclonal F(ab’)2 antibodies in COVID-19 patients, including VOC carriers. In order to save lives and reduce the use and costs of critical care, this therapeutic solution is expected to reduce at least by 50% ICUs admissions and a highly significant mortality rate of treated patients.</p><p> </p><p>To optimize the indications for the treatment, potency and breath of F(ab’)2 against variants will be assessed in in vitro and in an animal model as well as prospective studies will respectively be done on immune assessment in treated patients and on mitigation of exacerbated immune responses in vivo.</p><p> </p><p>Fab’entech will coordinate EPIC-CROWN-2 formed by outstanding experts in different project domains that include clinical trials (HISS, Greece), virology (IMAS12, Spain), and immunopathology models and mitigation (BNITM, Germany - IRD, France). Most of them having already been working together in European projects. Importantly, EPIC CROWN 2 will be integrated as part of both the large European trial network EU-RESPONSE and the multinational European Adaptive Platform Trial “Solid Act".</p><p> </p></p>
</div>
</div><!-- end block abstract-->
</div>
<!-- block objectif-->
<div class="col-md-12">
<div class="objectif row" style="text-align:justify;">
<div class="preview-collapse collapsed" data-toggle="collapse" data-target="#collapseObjectif" aria-expanded="false" aria-controls="collapseObjectif">
<div class="col-lg-3 col-md-4 col-sm-12 col-xs-12">
<svg id="objective" class="ico" data-name="objective" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><title>Objectives</title><path d="M426.74,168.94a8,8,0,0,0-3.36,10.8,215.87,215.87,0,1,1-91.08-91.1,8,8,0,1,0,7.44-14.16,231.87,231.87,0,1,0,97.81,97.83A8,8,0,0,0,426.74,168.94Z" transform="translate(0 0)"/><path d="M334.71,136.84a8,8,0,0,0-2.33-11.07A183.29,183.29,0,0,0,232,96C130.54,96,48,178.54,48,280s82.54,184,184,184,184-82.54,184-184a183.3,183.3,0,0,0-29.74-100.34,8,8,0,0,0-13.4,8.74A167.34,167.34,0,0,1,400,280c0,92.64-75.36,168-168,168S64,372.64,64,280s75.36-168,168-168a167.34,167.34,0,0,1,91.64,27.17A8,8,0,0,0,334.71,136.84Z" transform="translate(0 0)"/><path d="M306.64,175.7a8,8,0,0,0-2.53-11A135.65,135.65,0,0,0,232,144c-75,0-136,61-136,136s61,136,136,136,136-61,136-136a135.64,135.64,0,0,0-20.67-72.11,8,8,0,0,0-13.56,8.49,120,120,0,1,1-38.15-38.16A8,8,0,0,0,306.64,175.7Z" transform="translate(0 0)"/><path d="M274.13,211.51a8,8,0,0,0-3.7-10.69A87.16,87.16,0,0,0,232,192a88,88,0,1,0,88,88,87.19,87.19,0,0,0-8.8-38.4,8,8,0,1,0-14.39,7A71.32,71.32,0,0,1,304,280a72,72,0,1,1-72-72,71.3,71.3,0,0,1,31.43,7.2A8,8,0,0,0,274.13,211.51Z" transform="translate(0 0)"/><path d="M227,256.53a8,8,0,0,0-3.33-15.65,40,40,0,1,0,47.54,47.18,8,8,0,1,0-15.67-3.21A24,24,0,1,1,227,256.53Z" transform="translate(0 0)"/><path d="M511.39,52.94A8,8,0,0,0,504,48H464V8a8,8,0,0,0-13.66-5.66l-100,100A8,8,0,0,0,348,108v44.69L226.34,274.34a8,8,0,0,0,11.31,11.31L359.31,164H404a8,8,0,0,0,5.66-2.34l100-100A8,8,0,0,0,511.39,52.94ZM400.69,148H375.31l62.34-62.34a8,8,0,1,0-11.31-11.31L364,136.69V111.31l84-84V56a8,8,0,0,0,8,8h28.69Z" transform="translate(0 0)"/></svg>
<h3> Objectives </h3>
</div>
<div class="col-lg-9 col-md-8 col-sm-12 col-xs-12">
<p><p><b>Objective 1: To assess beneficial impacts of this treatment and to optimise the therapeutic indications through European multicentric clinical studies Phase II a/b on 16 and 400 patients, respectively.</b></p><p> </p><p>EPIC-CROWN-2 is aiming to provide a holistic therapeutic approach for COVID-19. This is comprising the conduct of one phase IIa study and of one phase IIb study.</p>
</div>
</div>
<div class="collapse col-lg-9 col-md-8 col-lg-offset-3 col-md-offset-4 col-sm-12" id="collapseObjectif">
<p> With these studies EPIC-CROWN-2 shows completeness for three main reasons: (i) the phase IIa study that will provide all necessary information on pharmacokinetics and safety; (ii) the phase IIb study that will provide the safety and efficacy of FBR-002 in the clinical practice. To this end, the phase IIb study is comprising one double-blind randomized design and aims to demonstrate how early start of treatment with FBR-002 may prevent progression of severe respiratory failure, which is the most threatening complication of COVID-19; (iii) In the same aspect EPIC-CROWN-2 is also trying to provide one robust response to the question whether FBR-002 is showing clinical benefit when administered to patients irrespective of the variant of SARS-CoV-2.</p><p> </p><p><b>Objective 2: To analyse the impact of SARS-CoV-2 VOC within clinical batches of polyclonal F(ab’)2 (FBR-002) antibodies by <em>in vitro</em> and <em>in vivo</em> studies.</b></p><p> </p><p>Circulation of SARS-CoV-2 variants has raised concerns, since changes on the spike protein and specially in the receptor-binding domain (RBD) region are associated with an increased transmissibility and can also determine immune escape to neutralizing antibodies induced by natural infection or vaccination. New appearance of VOCs is expected in the context of high pandemic activity as it has been the case in South Africa were the new VOC “Omicron” (B.1.617) has been recently described, which was then rapidly detected in several European countries. The impact of VOCs on new therapeutics is largely unknown and a number of monoclonal antibodies have been rendered inactive against this latest VOC.</p><p>A polyclonal approach targeting multiple epitopes could more easily counteract the scape properties of specific mutations. We have aimed to investigate the neutralizing magnitude and breadth against circulating and future VOC of clinical batches of FBR-002 antibodies both <em>in vitro</em> and an <em>in vivo</em> model of SARS-CoV-2 infection.</p><p> </p><p><b>Objective 3: Prospective clinical and <em>in vivo</em> studies to improve the indications of the treatment.</b></p><p> </p><p>Considering that the main scope of this project is to assess an EMA-authorized anti-SARS-CoV-2 immunotherapeutic approach based upon clinical GMP batches of potent and broad horse polyclonal anti-SARS-CoV-2 F(ab’)2 antibodies in COVID-19 patients infected by VOC, it is important to assess beneficial impacts of this treatment that obviously will depend on the patient’s inclusion criteria, administration route and dosage. To optimize the therapeutic indications, one of the key aspects are the inclusion criteria. Among these criteria, immune status is one of the most important, since they depend on general health status of patients exhibiting or not co-morbidities or particular genetic characteristics. To contribute to accurately assess the impact of the treatment, the clinicians will assess the general health status (the most important criteria) of FBR-002-treated patients to accurately provide clinical data on the determined endpoints of efficacy.</p><p>We propose to complete these clinical observations with prospective studies on (i) the assessment of the clinical evolution of virological and immune parameters (innate and adaptive) before and after the FBR-002 treatment in patients and (ii) the characterization of some possible biomarkers that could prospectively help to both accurately assess the impact of the FBR-002 treatment beyond the general health status, as well as to prospectively define the inclusion criteria, which will help to optimize the indications for this treatment.</p><p>In addition, prospective <em>in vitro</em> (IRD) and <em>in vivo</em> (small animal model at BNITM) experiments will be done to fine-tune patented lead compounds (issued from biomarkers studied) that have already shown critical protective effects on exacerbated loss of the integrity and function of endothelial and epithelial barriers. If a clear <em>in vivo</em> efficacy proof of concept is done, therefore clinical studies could be then proposed with these compounds. Ultimately, these compounds could be as one tier for potential combined mitigation of ARDS in severe COVID-19.</p><p> </p><p><b>Objective 4: Preparation of the market uptake to timely access to GMP production to be trialled and strategy definition for the upscale production.</b></p><p> </p><p>This objective runs along two main axes:</p><ul> <li>The consolidation of the exploitation plan including production upscaling, regulatory and marketing strategy to address the market in the different outbreak scenarios (new peaks, seasonal outbreak, outbreak disappears);</li> <li>Raise awareness and prepare for uptake of the EPIC-CROWN-2 solution by disseminating and engaging with the scientific community, practitioner community, Key Opinion Leaders (KOL) and decision-makers.</li></ul><p> </p><p>To ensure and maximise the impact, the EPIC-CROWN-2 project has developed a concrete and feasible plan for the industrial production and scale-up of FBR-002 production. This plan will enable a step-by-step implementation depending on public health needs in terms of treatment as well as the capacity to finance it.</p><p>The FAB production facilities of highly-purified specific large-scale production of F(ab’)2 immunotherapy using already available antigens (since July 2020) enables fast deployment and scale-up of the anti-COVID-19 immunotherapy solution developed in the project.</p></p>
</div>
</div>
</div>
<!-- end block objectif-->
</div>
</div>
</div>
</section><!-- end section project -->
<!-- block results-->
<!-- block exploitation-->
<!-- VIDEOS -->
<section id="video" data-scroll-index="3">
<div class="bg-light">
<div class="container">
<h2 class="hidden-xs"> Videos </h2>
<h2 class="visible-xs h2-mobile"> <a href="#" class="active">video</a> / <a href="#">video</a> </h2>
</div>
</div>
<div class="bg-light">
<div class="container">
<div class="row">
<div class="col-sm-12">
<ul class="bxslidervideo">
<li>
<div class="video-container" style="width:1040px; height:600px; padding-top:0px;">
<div style="width:1040px; height:600px;">
<iframe src="https://www.youtube.com/embed/2jPU9xDA2C0?si=qb9YhIDLNaPSJHcy?rel=0&showinfo=0" frameborder="0" allowfullscreen=""></iframe>
</div></div>
</li>
<li>
<div class="video-container" style="width:1040px; height:600px; padding-top:0px;">
<div style="width:1040px; height:600px;">
<iframe src="https://www.youtube.com/embed/_3oVYOSBTiA?si=z5qfY5g6cjathMty?rel=0&showinfo=0" frameborder="0" allowfullscreen=""></iframe>
</div></div>
</li>
<li>
<div class="video-container" style="width:1040px; height:600px; padding-top:0px;">
<div style="width:1040px; height:600px;">
<iframe src="https://www.youtube.com/embed/m6K13kAHkN0?si=2sCcSR7Xk1WB-fP-?rel=0&showinfo=0" width="560" height="315" frameborder="0" webkitAllowFullScreen mozallowfullscreen allowFullScreen></iframe>
</div></div>
</li>
<li>
<div class="video-container" style="width:1040px; height:600px; padding-top:0px;">
<div style="width:1040px; height:600px;">
<iframe src="https://www.youtube.com/embed/h0rXTjAmnYM?si=1zX_NIRMajlEZR8Z?rel=0&showinfo=0" width="560" height="315" frameborder="0" webkitAllowFullScreen mozallowfullscreen allowFullScreen></iframe>
</div></div>
</li>
<li>
<div class="video-container" style="width:1040px; height:600px; padding-top:0px;">
<div style="width:1040px; height:600px;">
<iframe src="https://www.youtube.com/embed/O-Ap0_u6JFA?si=yUlHhec0Q0ozlry9?rel=0&showinfo=0" width="560" height="315" frameborder="0" webkitAllowFullScreen mozallowfullscreen allowFullScreen></iframe>
</div></div>
</li>
<li>
<div class="video-container" style="width:1040px; height:600px; padding-top:0px;">
<div style="width:1040px; height:600px;">
<iframe src="https://www.youtube.com/embed/pHct7NmWi-o?si=vo5kIyqR80LNvCgE?rel=0&showinfo=0" width="560" height="315" frameborder="0" webkitAllowFullScreen mozallowfullscreen allowFullScreen></iframe>
</div></div>
</li>
</ul>
</div>
</div>
</div>
</div>
</section>
<!-- END VIDEOS -->
<!-- section partners-->
<section id="partners" data-scroll-index="4">
<div class="bg-light">
<div class="container">
<h2 class="hidden-xs"> partners </h2>
<h2 class="visible-xs h2-mobile"> <a href="#" class="active">partners</a> / <a href="#">contact</a> </h2>
<!--<ul class=" tabs visible-xs">
<li class="active"> <a href="#"> Partners </a> </li>
<li> <a href="#"> Contact </a> </li>
</ul>-->
<div class="row">
<div class="col-lg-3 col-md-3 col-sm-4 col-xs-12 article-partner" >
<div class="flip">
<div class="front"> <div class="arrow-right"> </div>
<p class="container-img">
<img class="img-responsive center-block" src="upload/epiccrown2/website/logo-new-1536x160.png" alt="">
</p>
<p class="company" > FABENTECH </p>
<p class="companyshort"> [ FAB ] </p>
<p class="country"> France </p>
<p class="name-contact"> Anaïs Belledant </p>
</div>
<div class="back">
<div class="arrow-left"> </div>
<div class="top-back">
<img class="img-circle img-responsive center-block" src="upload/epiccrown2/website/user_16280.jpeg">
<h4> Anaïs Belledant </h4>
<p> </p>
</div>
<div class="row social" >
<div class="col-xs-4">
</div>
<div class="col-xs-4">
<a href="mailto:anais.belledant@fabentech.com">
<img src="img/website/mail.png" class="img-responsive center-block">
</a>
</div>
<div class="col-xs-4">
<a href="https://www.linkedin.com/in/ana%C3%AFs-belledant-0bb56ab0/" target="_blank">
<img src="img/website/linkedin.png" class="img-responsive center-block">
</a>
</div>
</div>
</div>
</div>
</div>
<div class="col-lg-3 col-md-3 col-sm-4 col-xs-12 article-partner" >
<div class="flip">
<div class="front"> <div class="arrow-right"> </div>
<p class="container-img">
<img class="img-responsive center-block" src="upload/epiccrown2/website/Logo_IRD_2016_BLOC_FR_COUL.png" alt="">
</p>
<p class="company" > INSTITUT DE RECHERCHE POUR LE DEVELOPPEMENT </p>
<p class="companyshort"> [ IRD ] </p>
<p class="country"> France </p>
<p class="name-contact"> Francisco Veas </p>
</div>
<div class="back">
<div class="arrow-left"> </div>
<div class="top-back">
<img class="img-circle img-responsive center-block" src="img/website/default-contact.png">
<h4> Francisco Veas </h4>
<p> </p>
</div>
<div class="row social" >
<div class="col-xs-4">
</div>
<div class="col-xs-4">
<a href="mailto:francisco.veas@ird.fr">
<img src="img/website/mail.png" class="img-responsive center-block">
</a>
</div>
</div>
</div>
</div>
</div>
<div class="col-lg-3 col-md-3 col-sm-4 col-xs-12 article-partner" >
<div class="flip">
<div class="front"> <div class="arrow-right"> </div>
<a href="https://imas12.es/en" target="_blank">
<p class="container-img">
<img class="img-responsive center-block" src="upload/epiccrown2/website/logo imas12 sin fondo blanco.png" alt="">
</p>
</a>
<p class="company" > Instituto de Investigación 12 de Octubre </p>
<p class="companyshort"> [ IMAS12 ] </p>
<p class="country"> Spain </p>
<p class="name-contact"> Rafael Delgado </p>
</div>
<div class="back">
<div class="arrow-left"> </div>
<div class="top-back">
<img class="img-circle img-responsive center-block" src="upload/epiccrown2/website/user_14430.jpg">
<h4> Rafael Delgado </h4>
<p> </p>
</div>
<div class="row social" >
<div class="col-xs-4">
<a href="https://imas12.es/en" target="_blank">
<img src="img/website/web.png" class="img-responsive center-block">
</a>
</div>
<div class="col-xs-4">
<a href="mailto:rafael.delgado@salud.madrid.org">
<img src="img/website/mail.png" class="img-responsive center-block">
</a>
</div>
</div>
</div>
</div>
</div>
<div class="col-lg-3 col-md-3 col-sm-4 col-xs-12 article-partner" >
<div class="flip">
<div class="front"> <div class="arrow-right"> </div>
<a href="https://www.sepsis.gr" target="_blank">
<p class="container-img">
<img class="img-responsive center-block" src="upload/epiccrown2/website/LOGO gr sepsis b.png" alt="">
</p>
</a>
<p class="company" > Hellenic Institute for the Study of Sepsis </p>
<p class="companyshort"> [ HISS ] </p>
<p class="country"> Greece </p>
<p class="name-contact"> Evangelos GIAMARELLOS-BOURBOULIS </p>
</div>
<div class="back">
<div class="arrow-left"> </div>
<div class="top-back">
<img class="img-circle img-responsive center-block" src="upload/epiccrown2/website/user_14431.jpg">
<h4> Evangelos GIAMARELLOS-BOURBOULIS </h4>
<p> </p>
</div>
<div class="row social" >
<div class="col-xs-4">
<a href="https://www.sepsis.gr" target="_blank">
<img src="img/website/web.png" class="img-responsive center-block">
</a>
</div>
<div class="col-xs-4">
<a href="mailto:egiamarel@med.uoa.gr">
<img src="img/website/mail.png" class="img-responsive center-block">
</a>
</div>
</div>
</div>
</div>
</div>
<div class="col-lg-3 col-md-3 col-sm-4 col-xs-12 article-partner" >
<div class="flip">
<div class="front"> <div class="arrow-right"> </div>
<a href="https://www.bnitm.de/en" target="_blank">
<p class="container-img">
<img class="img-responsive center-block" src="upload/epiccrown2/website/BNITM-LOGO-13-E.png" alt="">
</p>
</a>
<p class="company" > BERNHARD-NOCHT-INSTITUT FUER TROPENMEDIZIN </p>
<p class="companyshort"> [ BNITM ] </p>
<p class="country"> Germany </p>
<p class="name-contact"> Estefania RODRIGUEZ </p>
</div>
<div class="back">
<div class="arrow-left"> </div>
<div class="top-back">
<img class="img-circle img-responsive center-block" src="img/website/default-contact.png">
<h4> Estefania RODRIGUEZ </h4>
<p> </p>
</div>
<div class="row social" >
<div class="col-xs-4">
<a href="https://www.bnitm.de/en" target="_blank">
<img src="img/website/web.png" class="img-responsive center-block">
</a>
</div>
<div class="col-xs-4">
<a href="mailto:estefania.rodriguez@bnitm.de">
<img src="img/website/mail.png" class="img-responsive center-block">
</a>
</div>
</div>
</div>
</div>
</div>
<div class="col-xs-12 text-center hidden-xs">
<a class="btn" id="showcontact" href="#"> Show contact persons </a>
</div>
</div>
</div>
<!-- block europe-->
<div class="europe">
<div class="container">
<div class="row">
<div class="col-sm-2">
<img src="img/website/logo-europe.png" class="img-responsive center-block" alt="">
</div>
<div class="col-sm-10" >
<p>This project has received funding from the European Union’s Horizon Europe research and innovation programme under grant agreement No 101046084. This publication [communication] reflects the views only of the author, and the Commission cannot be held responsible for any use which may be made of the information contained therein.</p>
</div>
</div>
</div>
</div>
<!-- end block europe-->
</div>
<!-- block map-->
<div class="container-map" >
<div id="googlemaps"> </div>
</div>
</section>
<!-- section graph chart-->
<section id="graph-chart" data-scroll-index="5">
<div class="bg-light">
<div class="container">
<h2> graph - chart </h2>
<div class="row">
<!-- end block pie chart-->
<div class="col-sm-12">
<div class="wrapper-progress">
<div class="line">
<div class="start">
<span class="label"> Start </span>
<span class="date">01/06/2021 </span>
</div>
<div class="scale">
<div class="progression" style="width:100%;"></div>
<div class="avancement" style="left:100%;">
<span class="label"><span data-to="100">100</span>% </span>
</div>
</div>
<div class="end">
<span class="label"> End </span>
<span class="date">30/11/2023 </span>
</div>
</div>
</div>
</div>
</div>
<div class="row item-number">
<div class="col-sm-4 number">
<svg id="budget" class="icon-svg" data-name="Capa 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 612 612.02"><title>Budget allocation</title><path d="M592.88,306a286.9,286.9,0,1,0-84,202.85,286,286,0,0,0,84-202.85h0ZM522.38,89.63A306,306,0,1,1,306,0,305.06,305.06,0,0,1,522.38,89.63Z" transform="translate(-0.01 0)"/><path d="M86.1,344.22a9.52,9.52,0,1,1,0-19l229.51,0a9.52,9.52,0,1,1,0,19Z" transform="translate(-0.01 0)"/><path d="M400.83,400.26a9.56,9.56,0,0,1,13.53,13.53,153.37,153.37,0,0,1-49.61,33.13h0a152.76,152.76,0,1,1,49.61-249.19,9.56,9.56,0,0,1-13.53,13.53,133.54,133.54,0,1,0-43.39,218v0l0,0A133.26,133.26,0,0,0,400.83,400.26Z" transform="translate(-0.01 0)"/><path d="M124.35,286.84a9.52,9.52,0,0,1,0-19l229.49,0a9.52,9.52,0,0,1,0,19Z" transform="translate(-0.01 0)"/></svg>
<span> <span data-to="9"></span>.<span data-to="1"></span> <span class="unit">M€</span> </span>
<span class="label"> Budget allocation </span>
</div>
<div class="col-sm-4 number">
<svg id="effort2" class="icon-svg" data-name="Capa 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 611.98 611.99"><title>Effort</title><path d="M47.81,363.28a9.52,9.52,0,1,1,0-19l47.11,0.08,79.49-92.38a9.53,9.53,0,0,1,13.45-1,9.37,9.37,0,0,1,1.63,1.81l69,86.28L404,175.31a9.57,9.57,0,0,1,13.49-.8l0.77,0.8,87.08,87,31.79-47.69A9.53,9.53,0,1,1,553,225.21l-38,57a8.78,8.78,0,0,1-1.4,1.75,9.55,9.55,0,0,1-13.49,0l-88.53-88.45L265.33,360.1l0,0a12.57,12.57,0,0,1-1.17,1.11,9.52,9.52,0,0,1-13.37-1.49L181.43,273l-74.84,87,0,0a9.49,9.49,0,0,1-7.25,3.35l-51.5-.08h0Zm370-188.39,0.4,0.4Z" transform="translate(0 0)"/><path d="M296.47,57.35a9.56,9.56,0,0,1,0,19.12H19.13v344.4H592.86V76.48H334.66a9.56,9.56,0,0,1,0-19.12H602.42A9.57,9.57,0,0,1,612,66.92V430.44a9.57,9.57,0,0,1-9.56,9.56H9.56A9.57,9.57,0,0,1,0,430.44V66.91a9.57,9.57,0,0,1,9.56-9.56H296.47Z" transform="translate(0 0)"/><path d="M286.89,9.52a9.52,9.52,0,0,1,19,0l0,57.37a9.52,9.52,0,1,1-19,0Z" transform="translate(0 0)"/><path d="M286.93,468.53a9.52,9.52,0,1,1,19,0l0,95.68a9.52,9.52,0,0,1-19,0Z" transform="translate(0 0)"/><path d="M153.36,465.92a9.55,9.55,0,0,1,18.37,5.22L133.55,605a9.55,9.55,0,0,1-18.37-5.22Z" transform="translate(0 0)"/><path d="M421.14,471.14a9.55,9.55,0,1,1,18.37-5.22l38.23,133.91A9.55,9.55,0,1,1,459.37,605Z" transform="translate(0 0)"/><path d="M9.56,478.27a9.56,9.56,0,0,1,0-19.12H602.42a9.56,9.56,0,1,1,0,19.12H9.56Z" transform="translate(0 0)"/></svg>
<span> <span data-to="412">412</span> <span class="unit">p*m</span> </span>
<span class="label"> Effort </span>
</div>
<div class="col-sm-4 number">
<svg id="effort" class="icon-svg" data-name="Capa 1" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 612 612.02"><title>Effort</title><path d="M57,612a9.56,9.56,0,1,1,0-19.12H116.3a9.56,9.56,0,1,1,0,19.12H57Zm109.79,0a9.56,9.56,0,1,1,0-19.12H495.74a9.56,9.56,0,0,1,0,19.12H166.8Zm376.35,0h59.29a9.56,9.56,0,0,0,9.56-9.56v-0.28A306.17,306.17,0,0,0,398.68,310.79a9.52,9.52,0,1,0-5.76,18.15,287,287,0,0,1,199.8,263.93H543.16a9.57,9.57,0,0,0,0,19.15h0ZM213.34,310.79A306.1,306.1,0,0,0,0,602.44a9.56,9.56,0,0,0,19.13,0,286.92,286.92,0,0,1,200-273.5A9.52,9.52,0,0,0,213.34,310.79Z" transform="translate(-0.01 0)"/><path d="M306,0A157.75,157.75,0,0,1,417.59,269.31l0,0,0,0v0A157.75,157.75,0,0,1,194.47,46.26l0,0A157.13,157.13,0,0,1,306,0h0Zm98,59.75a138.64,138.64,0,1,0,0,196.14l0,0A138.76,138.76,0,0,0,404.06,59.75Z" transform="translate(-0.01 0)"/><path d="M306,0a157.05,157.05,0,0,1,95.43,32.17l0.6,0.5a157.94,157.94,0,0,1,56,83.06,9.55,9.55,0,0,1-6.63,11.73,9.39,9.39,0,0,1-2.55.36v0H327.58a83.93,83.93,0,0,1-59.37-24.7l0-.08a83.93,83.93,0,0,1-24.7-59.37V19.34a9.57,9.57,0,0,1,6.77-9.15A159.83,159.83,0,0,1,306,0h0Zm83.85,47.32A138.13,138.13,0,0,0,306,19.13a140.36,140.36,0,0,0-25.26,2.27,135.72,135.72,0,0,0-18.17,4.66V43.71a64.93,64.93,0,0,0,19,45.88l0.06,0.06a64.84,64.84,0,0,0,45.88,19H435.76a139.08,139.08,0,0,0-45.38-61Z" transform="translate(-0.01 0)"/><path d="M154.19,114.87A158.08,158.08,0,0,1,249.62,10.42a9.55,9.55,0,0,1,12.31,5.52,9.28,9.28,0,0,1,.62,3.41h0V43.71a83.9,83.9,0,0,1-24.7,59.37l0,0a83.93,83.93,0,0,1-59.37,24.7H163.12a9.57,9.57,0,0,1-9.56-9.56,10.06,10.06,0,0,1,.64-3.39h0Zm49.17-50.28a138.81,138.81,0,0,0-27.1,44.11h2.21a64.93,64.93,0,0,0,45.88-19l0,0a64.84,64.84,0,0,0,19-45.88V34A139.3,139.3,0,0,0,203.36,64.59Z" transform="translate(-0.01 0)"/><path d="M269.6,399.77l29.64-29.65a9.58,9.58,0,0,1,13.53,0l29.65,29.65a9.58,9.58,0,0,1,0,13.53l-29.65,29.64a9.58,9.58,0,0,1-13.53,0L269.6,413.29a9.58,9.58,0,0,1,0-13.53h0ZM306,390.42L289.9,406.54,306,422.66l16.12-16.12Z" transform="translate(-0.01 0)"/><path d="M347.7,558.87a9.54,9.54,0,0,1-17.95,6.49L306,499.76l-23.73,65.61a9.54,9.54,0,0,1-17.95-6.49L297,468.58a9.66,9.66,0,0,1,5.76-5.82A9.55,9.55,0,0,1,315,468.48Z" transform="translate(-0.01 0)"/><path d="M344.29,248.33a9.52,9.52,0,0,1,7.39,17.55,116.17,116.17,0,0,1-22.33,6.89A118.76,118.76,0,0,1,306,275.15a118.38,118.38,0,0,1-45.64-9.26,9.52,9.52,0,1,1,7.39-17.55,98.3,98.3,0,0,0,18.69,5.78A100.16,100.16,0,0,0,306.06,256,96.66,96.66,0,0,0,344.29,248.33Z" transform="translate(-0.01 0)"/><path d="M473,536.89a9.52,9.52,0,1,1,17.55-7.39,185.72,185.72,0,0,1,11,35.66,188.63,188.63,0,0,1,3.74,37.26,9.56,9.56,0,1,1-19.12,0A167.17,167.17,0,0,0,473,536.89Z" transform="translate(-0.01 0)"/><path d="M125.86,602.44a9.56,9.56,0,0,1-19.13,0,188.81,188.81,0,0,1,3.75-37.26,185.68,185.68,0,0,1,11-35.66A9.52,9.52,0,1,1,139,536.91,166.26,166.26,0,0,0,125.86,602.44Z" transform="translate(-0.01 0)"/><path d="M211.59,328.18a9.52,9.52,0,0,1,9.26-16.64A174.29,174.29,0,0,0,261.93,328l0,0v0A177.78,177.78,0,0,0,350,328l0.42-.1a173.27,173.27,0,0,0,40.7-16.32,9.52,9.52,0,0,1,9.26,16.64,193.45,193.45,0,0,1-45.24,18.11l-0.36.1a194.87,194.87,0,0,1-97.66,0v0A193.43,193.43,0,0,1,211.59,328.18Z" transform="translate(-0.01 0)"/></svg>
<span> <span data-to="14">14</span> <span class="unit">persons </span></span>
<span class="label"> Full time equivalent </span>
</div>
</div>
</div>
</div>
</section>
<!-- section news-->
<section id="news" data-scroll-index="6">
<div class="bg-photo">
<div class="container">
<h2> news </h2>
<div class="row" >
<div class="col-lg-3 col-md-4 col-sm-6">
<div class="article-news" id='news_6'>
<h3> EPIC CROWN 2 Introduces its Gender Equality P... </h3>
<p class="date"> 2023-10-09 </p>
<p> <p>In alignment with our project's core values and commitment to fostering an inclusive research environment, EPIC CROWN 2 is... </p>
<a href="#" class="viewmore" id="a_news_6" data-toggle="modal" data-target="#myModal" data-title="EPIC CROWN 2 Introduces its Gender Equality Plan (GEP)" data-text='<p>In alignment with our project's core values and commitment to fostering an inclusive research environment, EPIC CROWN 2 is pleased to announce the implementation of a <b>Gender Equality Plan</b> (GEP). This strategic step emphasizes our dedication to promoting gender equality within the research and academic sphere.</p><p>Our GEP is based on the guidelines set by the European Commission's Gender Equality in Academia and Research (GEAR) tool. This framework has been recognized for its comprehensive approach to addressing gender disparities in research and academia.</p><p>Key Components of Our GEP:</p><ul> <li> <p><b>Audit Phase</b>: This initial step involves gathering gender-disaggregated data and conducting a review of existing practices within the project. The aim is to identify any areas of inequality and understand their root causes.</p> </li> <li> <p><b>Planning Phase</b>: Based on the insights from the audit, clear objectives and targets are set. A detailed action roadmap is developed, outlining the steps needed to achieve these objectives.</p> </li> <li> <p><b>Implementation Phase</b>: Here, the formulated strategies are put into action. This involves the creation of dedicated working groups, awareness initiatives, and training sessions to ensure that the GEP's principles are seamlessly integrated into our project's operations.</p> </li> <li> <p><b>Monitoring & Evaluation Phase</b>: The effectiveness of the GEP is continuously assessed through regular reviews. Feedback from these evaluations will inform any necessary adjustments or improvements, ensuring the plan remains dynamic and responsive to the project's needs.</p> </li></ul><p><b>Gender equality is a crucial pillar for innovation, growth, and progress. By instituting this GEP, EPIC CROWN 2 aims to create a project environment where all contributors feel valued, represented, and empowered to bring their best to the table.</b></p><p><b>► Find our GEP under the "documents" section of this website!</b></p><p>For more details on our GEP and its subsequent developments, keep an eye on our updates. We are committed to sharing our progress and learnings as we further integrate gender equality into the fabric of our project.</p><br><img class="img-responsive center-block" src="upload/epiccrown2/news/news_9876_gender epic.PNG" alt="">' onClick="gtag('event','news',{ event_category:'click_news_card', event_label:'EPIC CROWN 2 Introduces its Gender Equality P...'})"> View more </a>
</div>
</div>
<div class="col-lg-3 col-md-4 col-sm-6">
<div class="article-news" id='news_12'>
<h3> Check our Project Poster! </h3>
<p class="date"> 2023-09-01 </p>
<p> <p>We are excited to share the newest advancements in the EPIC CROWN 2 project. Our team has been diligently working on both... </p>
<a href="#" class="viewmore" id="a_news_12" data-toggle="modal" data-target="#myModal" data-title="Check our Project Poster!" data-text='<p>We are excited to share the newest advancements in the EPIC CROWN 2 project. Our team has been diligently working on both preclinical and clinical data, paving the way for further insights into the battle against COVID-19.</p><p>Dr. Anaïs Belledant from Fab'entech has recently presented our latest findings, encapsulated in the poster titled: <b>A18: Equine Polyclonal Antibodies Immunotherapy Against COVID-19/SARS-CoV-2-VOC.</b></p><p>For those seeking a comprehensive understanding of our recent developments, we encourage you to review the detailed poster. The data presented therein sheds light on our ongoing efforts to harness equine polyclonal antibodies as a potential therapeutic avenue against the virus.</p><p>At EPIC CROWN 2, our commitment to innovative solutions remains steadfast, and we are proud to have Dr. Belledant lead and present these crucial project milestones.</p><br><img class="img-responsive center-block" src="upload/epiccrown2/news/news_9876_posterepic.PNG" alt="">' onClick="gtag('event','news',{ event_category:'click_news_card', event_label:'Check our Project Poster!'})"> View more </a>
</div>
</div>
<div class="col-lg-3 col-md-4 col-sm-6">
<div class="article-news" id='news_7'>
<h3> EPIC CROWN 2 Showcased at ENVISION Pitch Talks </h3>
<p class="date"> 2023-07-05 </p>
<p> <p>We are excited to share that EPIC CROWN 2 made a prominent appearance at the renowned ENVISION pitch talks. <b>Anaïs Belledant,...</b> </p>
<a href="#" class="viewmore" id="a_news_7" data-toggle="modal" data-target="#myModal" data-title="EPIC CROWN 2 Showcased at ENVISION Pitch Talks" data-text='<p>We are excited to share that EPIC CROWN 2 made a prominent appearance at the renowned ENVISION pitch talks. <b>Anaïs Belledant, our esteemed project coordinator from Fab'entech</b>, represented the project and highlighted its key aspects.</p><p>ENVISION pitch talks serve as a dynamic platform where groundbreaking projects, innovations, and ideas are presented to a discerning audience comprising industry leaders, researchers, and enthusiasts. Having EPIC CROWN 2 spotlighted at such a prestigious event reinforces the project's significance and potential impact in the domain.</p><p>Anaïs eloquently detailed the project's objectives, methodologies, and progress. Her presentation not only emphasized the project's dedication to research excellence but also its commitment to fostering an inclusive environment in academia and research.</p><p>Feedback from attendees was very positive, showcasing the resonance and relevance of EPIC CROWN 2's mission and goals in today's research landscape.</p><p><b>We are proud of Anaïs for effectively communicating the essence of our project and are excited about the collaborations and opportunities this exposure might bring!</b></p><p>Stay tuned for more updates and milestones from EPIC CROWN 2 as we continue to push the boundaries of research and innovation.</p>' onClick="gtag('event','news',{ event_category:'click_news_card', event_label:'EPIC CROWN 2 Showcased at ENVISION Pitch Talks'})"> View more </a>
</div>
</div>
<div class="col-lg-3 col-md-4 col-sm-6">
<div class="article-news" id='news_8'>
<h3> Dr. Anaïs Belledant of EPIC CROWN 2 to Speak... </h3>
<p class="date"> 2023-06-27 </p>
<p> <p><b>Dr. Anaïs Belledant, the Project Manager of EPIC CROWN 2, has been listed as an expert speaker for the upcoming "Highway to...</b> </p>
<a href="#" class="viewmore" id="a_news_8" data-toggle="modal" data-target="#myModal" data-title="Dr. Anaïs Belledant of EPIC CROWN 2 to Speak at Highway to Health 2023" data-text='<p><b>Dr. Anaïs Belledant, the Project Manager of EPIC CROWN 2, has been listed as an expert speaker for the upcoming "Highway to Health 2023" event. This policy and cluster event, scheduled for July 4th, 2023 in Brussels, focuses on the future trajectory of healthcare in Europe.</b></p><p>With a solid background in the pharmaceutical industry and molecular medicine, Dr. Belledant currently holds a position in Responsible Innovation at Fab'entech. Her scientific contributions encompass areas such as oncogenetic, cytological, and immunohistological analyses, as well as clinical studies.</p><p>Alongside Dr. Belledant, the event will feature other experts like Dr. Wolfgang Brysch from MetrioPharm and Dr. Timothée Dub from the Finnish Institute for Health and Welfare (THL).</p><p>For individuals and professionals interested in participating in "Highway to Health 2023", registration options are available for both remote and in-person attendance. Further details and the registration process can be accessed through <a href="https://lnkd.in/ej4a_AA2" target="_new">this link</a>.</p><p>EPIC CROWN 2 acknowledges Dr. Belledant's selection as a testament to her expertise and the project's significance in the broader healthcare landscape.</p><br><img class="img-responsive center-block" src="upload/epiccrown2/news/news_9876_anaishealth.PNG" alt="">' onClick="gtag('event','news',{ event_category:'click_news_card', event_label:'Dr. Anaïs Belledant of EPIC CROWN 2 to Speak...'})"> View more </a>
</div>
</div>
<div class="col-lg-3 col-md-4 col-sm-6">
<div class="article-news" id='news_9'>
<h3> Join EPIC CROWN 2 LinkedIn Page! </h3>
<p class="date"> 2023-06-13 </p>
<p> <p>We are pleased to announce that the EPIC CROWN 2 project is broadening its reach by enhancing its public presence,... </p>
<a href="#" class="viewmore" id="a_news_9" data-toggle="modal" data-target="#myModal" data-title="Join EPIC CROWN 2 LinkedIn Page!" data-text='<p>We are pleased to announce that the EPIC CROWN 2 project is broadening its reach by enhancing its public presence, particularly on professional networking platforms such as LinkedIn.</p><p>To offer a comprehensive insight into our project's trajectory, we have also released a video presentation on our official website. This presentation showcases the notable progress and pioneering discoveries accomplished by our dedicated team. We encourage everyone to view it for a deeper understanding of our initiatives: <a href="https://epic-crown-2.com/" target="_new">EPIC CROWN 2 Video Presentation</a>.</p><p>This increased visibility is part of our continued commitment to keep stakeholders, collaborators, and the general public informed about the latest developments, insights, and milestones achieved under the EPIC CROWN 2 umbrella, which proudly receives funding from the European Commission.</p><p>Our core mission remains unwavering: to contribute significantly in the ongoing fight against COVID-19 through innovative strategies and solutions.</p><p>To stay updated with our latest announcements and breakthroughs, consider following our <a href="https://www.linkedin.com/company/epic-crown-2/" target="_new">LinkedIn page</a>.</p><p>Thank you for your continued support and engagement as we move forward in this crucial journey.</p><br><img class="img-responsive center-block" src="upload/epiccrown2/news/news_9876_linkedin.PNG" alt="">' onClick="gtag('event','news',{ event_category:'click_news_card', event_label:'Join EPIC CROWN 2 LinkedIn Page!'})"> View more </a>
</div>
</div>
<div class="col-lg-3 col-md-4 col-sm-6">
<div class="article-news" id='news_10'>
<h3> EPIC CROWN 2 Project Holds General Assembly i... </h3>
<p class="date"> 2023-06-01 </p>
<p> <p>The EPIC CROWN 2 consortium recently convened for its General Assembly in Madrid, hosted at the prestigious 𝐶𝑜𝑙𝑒𝑔𝑖𝑜 𝑂𝑓𝑖𝑐𝑖𝑎𝑙 𝑑𝑒... </p>
<a href="#" class="viewmore" id="a_news_10" data-toggle="modal" data-target="#myModal" data-title="EPIC CROWN 2 Project Holds General Assembly in Madrid" data-text='<p>The EPIC CROWN 2 consortium recently convened for its General Assembly in Madrid, hosted at the prestigious 𝐶𝑜𝑙𝑒𝑔𝑖𝑜 𝑂𝑓𝑖𝑐𝑖𝑎𝑙 𝑑𝑒 𝑙𝑜𝑠 𝑚𝑒𝑑𝑖𝑐𝑜𝑠.</p><p>This significant gathering provided an opportunity for all members of the consortium to come together, reflecting on the advancements made over the recent months. Central to the day's discussions was our collective endeavor to develop an innovative treatment for Covid-19. Through collaborative deliberations and knowledge exchange, the assembly served as a platform to ensure alignment and momentum in our project's objectives.</p><p>We remain grateful for the commitment and expertise of every member, as together we continue our dedicated efforts to address the challenges presented by Covid-19.</p><p>Stay tuned for more updates on our project's progression and milestones.</p><br><img class="img-responsive center-block" src="upload/epiccrown2/news/news_9876_ec2 ga2.PNG" alt="">' onClick="gtag('event','news',{ event_category:'click_news_card', event_label:'EPIC CROWN 2 Project Holds General Assembly i...'})"> View more </a>
</div>
</div>
<div class="col-lg-3 col-md-4 col-sm-6">
<div class="article-news" id='news_11'>
<h3> EPIC CROWN 2 Project Presented at I4ID Congre... </h3>
<p class="date"> 2022-11-23 </p>
<p> <p>Dr. Anaïs Belledant of Fab'entech represented the EPIC CROWN 2 project at the 6th edition of the Immunotherapies & Innovations... </p>
<a href="#" class="viewmore" id="a_news_11" data-toggle="modal" data-target="#myModal" data-title="EPIC CROWN 2 Project Presented at I4ID Congress in Lyon" data-text='<p>Dr. Anaïs Belledant of Fab'entech represented the EPIC CROWN 2 project at the 6th edition of the Immunotherapies & Innovations for Infectious Diseases (I4ID) Congress held in Lyon. Dr. Belledant delivered a presentation detailing the project's goals, progress, and significance in the context of current infectious disease research.</p><p>For those interested in the specifics of the presentation, a poster detailing the EPIC CROWN 2 project, as presented by Dr. Belledant during the Congress, is available. You can access and view the poster via our <a href="https://lnkd.in/eS5eF-7j" target="_new">LinkedIn post</a>.</p><p>Fab'entech is proud to be associated with the EPIC CROWN 2 project and to have had the opportunity to share our work at such a prestigious event.</p><br><img class="img-responsive center-block" src="upload/epiccrown2/news/news_9876_epic poster.PNG" alt="">' onClick="gtag('event','news',{ event_category:'click_news_card', event_label:'EPIC CROWN 2 Project Presented at I4ID Congre...'})"> View more </a>
</div>
</div>
<div class="col-lg-3 col-md-4 col-sm-6">
<div class="article-news" id='news_5'>
<h3> Epic Crown 2 project passed review from Europ... </h3>
<p class="date"> 2022-10-11 </p>
<p> <p>It is time to celebrate! According to the reviewers from the European Commission, the Epic Crown 2 team has obtained very... </p>
<a href="#" class="viewmore" id="a_news_5" data-toggle="modal" data-target="#myModal" data-title="Epic Crown 2 project passed review from European Commission" data-text='<p>It is time to celebrate! According to the reviewers from the European Commission, the Epic Crown 2 team has obtained very interesting preclinical research findings demonstrating the promise of polyclonal antibodies to address multiple VoCs. We will keep working hard to achieve great results for the health sector!</p><p><a href="https://www.freepik.com/free-vector/group-medical-staff-carrying-health-related-icons_3226126.htm">Image by rawpixel.com</a> on Freepik</p><br><img class="img-responsive center-block" src="upload/epiccrown2/news/news_7475_group-of-medical-staff.jpg" alt="">' onClick="gtag('event','news',{ event_category:'click_news_card', event_label:'Epic Crown 2 project passed review from Europ...'})"> View more </a>
</div>
</div>
<div class="col-lg-3 col-md-4 col-sm-6">
<div class="article-news" id='news_3'>
<h3> General Assembly of Epic Crown 2 project </h3>
<p class="date"> 2022-05-16 </p>
<p> <p>Very fruitful General Assembly with all partners from the Epic Crown 2 consortium last week, in Attikon University Hospital,... </p>
<a href="#" class="viewmore" id="a_news_3" data-toggle="modal" data-target="#myModal" data-title="General Assembly of Epic Crown 2 project" data-text='<p>Very fruitful General Assembly with all partners from the Epic Crown 2 consortium last week, in Attikon University Hospital, Greece.</p><p>Special thanks to Pr Giamarellos-Bourboulis for hosting all partners for this very important meeting. This helped us a lot to coordinate this Horizon Europe project.</p><p>In a nutshell, great exchanges with european colleagues and partners from the Bernard Nocht Institute (Germany), the Hospital Universitario 12 de Octubre (Spain) , the Institute for Reasearch and Development (France) and the Hellenic Institute for the Study of Sepsis (Greece).</p><br><img class="img-responsive center-block" src="upload/epiccrown2/news/news_7475_epic meeting.jpeg" alt="">' onClick="gtag('event','news',{ event_category:'click_news_card', event_label:'General Assembly of Epic Crown 2 project'})"> View more </a>
</div>
</div>
<div class="col-lg-3 col-md-4 col-sm-6">
<div class="article-news" id='news_2'>
<h3> Objectives of the Epic Crown 2 project </h3>
<p class="date"> 2022-02-03 </p>
<p> <p><b>Objective 1</b>: To assess beneficial impacts of this treatment and to optimise the therapeutic indications through European... </p>
<a href="#" class="viewmore" id="a_news_2" data-toggle="modal" data-target="#myModal" data-title="Objectives of the Epic Crown 2 project" data-text='<p><b>Objective 1</b>: To assess beneficial impacts of this treatment and to optimise the therapeutic indications through European multicentric clinical studies Phase II a/b on 16 and 400 patients, respectively.</p><p><b>Objective 2</b>: To analyse the impact of SARS-CoV-2 VOC within clinical batches of polyclonal F(ab’)2 (FBR-002) antibodies by <em>in vitro</em> and <em>in vivo</em> studies.</p><p><b>Objective 3</b>: Prospective clinical and <em>in vivo</em> studies to improve the indications of the treatment.</p><p><b>Objective 4</b>: Preparation of the market uptake to timely access to GMP production to be trialled and strategy definition for the upscale production.</p><p> </p>' onClick="gtag('event','news',{ event_category:'click_news_card', event_label:'Objectives of the Epic Crown 2 project'})"> View more </a>
</div>
</div>
</div>
</div>
</div>
</section>
<!-- section events-->
<section id="events" data-scroll-index="7">
<div class="bg-light">
<div class="container">
<h2> events </h2>
<div class="timeline">
<!-- article event-->
<div class="article-event">
<span class="date"> 2023-01-06 </span>
<h3> Second General Assembly in Madrid </h3>
<p> <p>We began 2023 with an invigorating General Assembly in Madrid on January 6-7. The assembly allowed us to share updates on the progress of our Work Packages and discuss strategic next steps. A highlight of the assembly was the presentation of our esteemed scientific board, which provided valuable insights and further propelled our mission. This event was a testament to our ongoing dedication and collaboration in the fight against COVID-19 with innovative antiviral therapies.</p> </p>
</div>
<!-- end article event-->
<!-- article event-->
<div class="article-event">
<span class="date"> 2022-05-12 </span>
<h3> First Project General Assembly in Athens </h3>
<p> <p>We successfully conducted our first General Assembly on May 12, 2022, in Athens. This assembly brought together our distinguished team of experts to review our progress since the project's kick-off and strategize for the future. It was an opportunity to reflect on our achievements and plan further advancements in our mission against COVID-19. A momentous step in our journey towards innovative antiviral therapies.</p> </p>
</div>
<!-- end article event-->
<!-- article event-->
<div class="article-event">
<span class="date"> 2021-12-14 </span>
<h3> Kick-Off Meeting in Lyon </h3>
<p> <p>Project Kick-Off Meeting: We are excited to announce that the EPIC CROWN 2 project was officially launched on December 14, 2021. This pivotal kick-off meeting was held in Lyon, where our dedicated team of experts convened to set the strategic direction for our groundbreaking work in antiviral therapies. This significant milestone marked the start of our collective journey in the global fight against COVID-19.</p> </p>
</div>
<!-- end article event-->
</div>
</div>
</div>
</section>
<!-- section documents-->
<section id="documents" data-scroll-index="8">
<div class="bg-photo">
<div class="bg-color">
<div class="container">
<h2> documents </h2>
<div class="row">
<div class="col-sm-12" style="font-size:20px;"><b>DELIVERABLES</b></div>
<div class="article-doc" style="padding-left:5%;" >
<div class="col-sm-10">
<p> D1.5 Gender Equality Plan </p>
</div>
<div class="col-sm-2">
<a target="_blank" onClick="gtag('event','document',{ event_category:'download', event_label:'D1.5 Gender Equality Plan'})" href="https://projectnetboard.absiskey.com/viewdocument/924130-7d29a9-0cb575-ba495a-000025" download >download</a>
</div>
</div>
<div class="article-doc" style="padding-left:5%;" >
<div class="col-sm-10">
<p> Epic Crown 2 - Newsletter - 🔍 Curious about the various actions and results achieved by our team over the last few years? Our newsletter summarizes the essentials of the project, highlighting key milestones, impactful initiatives and project results. </p>
</div>
<div class="col-sm-2">
<a target="_blank" onClick="gtag('event','document',{ event_category:'download', event_label:'Epic Crown 2 - Newsletter'})" href="https://projectnetboard.absiskey.com/viewdocument/8ff04f-fbf098-4c3e0a-558f9f-000028" download >download</a>
</div>
</div>
<div class="col-sm-12" style="font-size:20px;"><b>Scientific Publications</b></div>
<div class="article-doc" style="padding-left:5%;" >
<div class="col-sm-10">
<p> Potent Neutralizing Activity </p>
</div>
<div class="col-sm-2">
<a target="_blank" onClick="gtag('event','document',{ event_category:'download', event_label:'Potent Neutralizing Activity'})" href="https://projectnetboard.absiskey.com/viewdocument/d276e2-31de9f-919154-5f46dd-000024" download >download</a>
</div>
</div>
</div>
</div>
</div>
</div>
</section>
<!-- REVEAL disclaimer -->
<!-- section form contact -->
<section id="contact" data-scroll-index="9">
<div class="bg-light">
<div class="container">
<h2> contact us </h2>
<div class="row"><!-- display:none; -->
<iframe id="frame_form" name="frame_form" style="display:none; width:0px; height: 0px;"></iframe>
<form method="post" target="frame_form" name="mailform" id="mailform" action="http://epic-crown-2.com/src/views/actions/websitemailnew_action.php" >
<input type="hidden" name="coordmail" value="anais.belledant@fabentech.com">
<input type="hidden" name="projectname" value="EPIC CROWN 2">
<div class="col-sm-6">
<div class="form-group">
<input type="text" class="form-control" id="Name" name="Name" placeholder="Name">
</div>
</div>
<div class="col-sm-6">
<div class="form-group">
<input type="email" class="form-control" id="Email" name="Email" placeholder="Email">
</div>
</div>
<div class="col-sm-12">
<div class="form-group">
<input type="text" class="form-control" id="Subject" name="Subject" placeholder="Subject">
</div>
</div>
<div class="col-sm-12">
<!--label></label-->
<textarea rows="8" class="form-control" id="Message" name="Message" placeholder="Message"></textarea>
</div>
<div class="col-sm-1">
<!--label></label-->
<input id="checkBox" class="form-control" type="checkbox">
</div>
<div class="col-sm-11" style="padding-top:10px;padding-bottom:20px;">
By submitting this form, I agree that the information entered may be used for newsletter subscriptions, information requests and statistical analysis that may result. Under no circumstances will these data be transferred to third parties.
<br>To know and exercise your rights, in particular to withdraw your consent to the use of data collected by this form, please consult our <a style="cursor: pointer;" id="alegal2">general conditions of use</a>.
</div>
<div class="col-sm-12">
<div class="form-group" id="div_ok" style="padding:5px 5px 5px 10px;" >
</div>
</div>
<!-- div class="col-sm-12">
<button type="button" class="btn" id="btn-contact"> Send </button>
</div -->
<div class="col-sm-12">
<div class="g-recaptcha" align="center" data-sitekey="6LcSpLMZAAAAAG5HWWrSGDUrqG5QzzTMe6ypVuTi" data-callback="correctCaptcha" data-expired-callback="recaptchaExpired"></div>
</div>
<div class="col-sm-12">
<div >
<button type="button" class="btn" id="btn-contact" name="testsubmite" disabled> Send </button>
</div>
</div>
</form>
</div>
</div>
</div>
</section>
<!-- section form login -->
<section id="loginsection" data-scroll-index="9">
<div class="bg-light">
<div class="container">
<h2> project netboard login </h2>
<div class="row">
<div class="col-sm-12" style="text-align:center;">
<p class="container-img">
<a target="_blank" href="https://projectnetboard.absiskey.com"><img src="img/logo-projectnetboard.png" class="img-responsive center-block" alt="project netboard login" ></a>
</p>
</div>
</div>
</div>
</div>
</section>
<!-- section footer-->
<footer>
<div class="light-grey">
<div class="container">
<div class="row">
<div class="col-sm-12">
<a href="https://www.absiskey.com"><img src="img/website/logo_abgi_new.png" style="width:250px;" alt=""></a>
<p>This service is a <a href="https://www.projectnetboard.com">Project netboard</a> module. Project netboard is a service by Absiskey. Please read these terms and conditions which govern your use of this site and its contents before proceeding any further. By consulting the pages of the site, you agree to observe these conditions.</p>
<a href="https://www.projectnetboard.com">www.projectnetboard.com</a><br>
<a href="https://www.absiskey.com">www.absiskey.com</a>
</div>
</div>
</div>
</div>
<div class="dark-grey">
<div class="container">
<div class="row">
<div class="col-sm-12">
<a id="alegal" style="cursor: pointer;" >Legal notices</a> | <a id="acharte" style="cursor: pointer;" > Personal data protection charter</a> | © 2026 absiskey, all rights reserved.
</div>
<div id="divlegal" style="text-align:justify;display:none;">
<br>
<br>Legal notices
<br>
<br>1. Use of the Absiskey and Project netboard Websites<br>
<br>In application of the Intellectual Property Code, any partial or total reproduction for collective use of the Absiskey et Project netboard Websites is strictly prohibited without express authorisation from Absiskey. In application of the intellectual property Code, any partial or total reproduction for collective use of Absiskey site is strictly forbidden without express authorisation from Absiskey.
<br>The user also agrees not to modify the domain https://www.absiskey.com, https://www.projectnetboard.com, https://projectnetboard.absiskey.com and its affiliated project websites, translate or transcribe it into any other language, transfer the data of the domains https://www.absiskey.com/ and https://www.projectnetboard.com, to any third party without prior permission Absiskey.
<br><br>
2. Use of the contents of the websites<br>
<br>Definition: the term "contents" used in this page shall be understood as follows: "contents" means any type of information, work, text, video, sound, animation, photograph or image contained on the websites.
<br>All content published on the https://www.absiskey.com/ and https://www.projectnetboard.com websites is the exclusive property of Absiskey or third parties whose exploitation rights have been obtained. Consequently, any representation or reproduction in whole or in part, made without the consent of the author or his successors in title, is illegal.
<br>All uses as described below require prior written permission:<br>
• Extraction, manipulation, modification of content in any way whatsoever;<br>
• Broadcasting, public representation of content;<br>
• Storage of content on any medium, including database, computer program or site extraction;<br>
• Commercial exploitation or publication of content in any way.<br>
<br>
3. Trademarks<br>
<br>A certain number of trademarks, logos or any other distinctive sign (collectively called trademarks) are represented on the websites. Absiskey trademarks and those of third parties represented on the websites are registered with the INPI (Institut National de la Propriété Industrielle) or protected by copyright. Nothing contained on the website may be used, added or exploited under any license or trademark right without the prior written consent of the owner.
<br><br>
4. Responsibility<br>
<br>The user of the www.absiskey.com and www.projectnetboard.com websites acknowledges having the necessary permissions, skills and means to access and use these websites. The user also acknowledges having verified that the computer configuration he uses contains no viruses and is in perfect working order. The user also acknowledges having read this legal notice and agrees to comply with it.
<br>Absiskey undertakes to implement all necessary means to ensure the best possible provision of the services it offers to the user. Nevertheless, Absiskey may not be held liable in the event of force majeure or de facto beyond its control, in particular in the event of interruption of service resulting from a failure of the telephone network or the Internet access provider of the Internet user.
<br>Finally, Absiskey provides links on its websites to websites of partner institutions and/or associations whose content does not involve Absiskey responsibility.
<br>RSS feeds are exclusively intended for visitors to absiskey.com projectnetboard.com sites for personal use and may not be used to feed other sites without the express prior agreement of Absiskey.
<br><br>
5. Use of personal data<br>
<br>Personal data submitted on the sites https://projectnetboard.absiskey.com and its affiliated project websites, are processed mainly for the following purposes:
<br>
• Managing your subscription to the publications of the project for which you are submitting your request; <br>
• The management of your information requests; <br>
• Internal statistical analysis<br>
<br>Absiskey keeps your data only for as long as necessary for the operations for which they were collected and in compliance with the law.
<br>In accordance with the law "Informatique et Liberté" of 6 January 1978, you have the right to access, alter, correct, and remove data that concerns you.
<br>You can exercise these rights by contacting the Director of the publication at the following e-mail address: rgpd at absiskey.com or by post to Absiskey, 41 bis rue Dupetit-Thouars, 49000 ANGERS (France), accompanied by a copy of a signed identity document.
<br><br>Web site Host: OVH 2 rue Kellermann - 59100 Roubaix - France
<br><br>© 2018, Absiskey. All rights reserved. Any reproduction of this work by any means whatsoever is prohibited without written permission from the publisher.
<br>
</div>
<div id="divcharte" style="text-align:justify;display:none;">
<br> <br> <br>
<br>PERSONAL DATA PRIVACY POLICY
<br>
<br>Absiskey is concerned about the protection of the privacy and data of its contacts and customers (users of its websites, including the Project netboard platform, contacts made in the context of professional meetings, missions, partnerships, applications, etc.).
<br>The purpose of this Privacy Policy is to inform in a clear and simple way the persons concerned ("the User") on the way Absiskey, as data controller, collects and uses personal data about you and on the means you have to control this use and exercise your rights relating to it.
<br>
<br><p style="text-decoration: underline;"><b>Article 1: Glossary </b></p>
For more clarity in the reading of the articles below,
<br>• "Publisher": is ABSISKEY
<br>• "Site": is one of the ABSISKEY websites accessible at the address https://projectnetboard.com
<br>• "User": is any person who visits one or more pages of the Site.
<br>
<br><p style="text-decoration: underline;"><b>Article 2 : Protection of personal data</b></p>
The Publisher undertakes to comply with the provisions :
<br>• European Regulation (EU) No. 2016/679 of 27 April 2016 on the protection of individuals with regard to the processing of personal data
<br>• Law n° 2018-493 of 20 June 2018 on the protection of personal data
<br>• law no. 78-17 of 6 January 1978 on information technology, files and freedoms, amended by various decrees including decree no. 2019-536 of 29 May 2019,
<br>• law n° 2004-575 of 21 June 2004 for confidence in the digital economy,
<br>• the code of posts and electronic communications, Book II on electronic communications.
<br>
<br><p style="text-decoration: underline;"><b>Article 3 - Data controller</b></p>
The person in charge of processing is ABSISKEY, François CHOLLET, President, 41 rue Dupetit Thouars, 49000 Angers.
<br>
<br><p style="text-decoration: underline;"><b>Article 4 - Legal basis for processing</b></p>
The legal basis for the processing is consent. It is the User who decides to connect to the Site, to fill in the contact form, who agrees (by ticking the box) that his data will be used for commercial relations, for the newsletter.
<br>
<br><p style="text-decoration: underline;"><b>Article 5 - Categories of data processed </b></p>
The categories of personal data collected are: e-mail of the User who fills in the form and any personal information that the User decides to include in his or her submission (e.g. name, first name, position, telephone number, etc.).
<br>
<br><p style="text-decoration: underline;"><b>Article 6 - Use of personal data collected via the sections</b></p>
The User may contact the Publisher or a member of the project via the "contact us" section.
The Editor does everything in its power to respond to any request sent by a User. Nevertheless, it does not undertake to acknowledge receipt of the User's request.
<br>
<br><p style="text-decoration: underline;"><b>Article 7 - Recipients of the personal data collected</b></p>
The Publisher and more precisely the recipients of the correspondence are the recipients of the personal data collected.
<br>No personal information of the User of the Site is published without the User's knowledge, exchanged, transferred, assigned or sold on any medium to third parties.
<br>Only the assumption of the purchase of the Publisher and its rights would allow the transmission of the said information to the eventual purchaser who would in turn be bound by the same obligation of conservation and modification of the data with respect to the User of the Site.
<br>
<br><p style="text-decoration: underline;"><b>Article 8 - Storage of collected personal data</b></p>
The personal data collected are kept for 1 year.
<br>
<br><p style="text-decoration: underline;"><b>Article 9 - Storage of personal data</b></p>
Personal data are not stored on the platform.
<br>
<br><p style="text-decoration: underline;"><b>Article 10 - Transfer of personal data</b></p>
There is no transfer of personal data outside the European Economic Area. The data collected through cookies are not considered as personal data as they do not allow the User to be identified.
<br>
<br><p style="text-decoration: underline;"><b>Article 11 - Right of access</b></p>
Each User has, in accordance with the legislation in force, a right of access to the personal data concerning him/her.
<br>The User may exercise this right by sending an e-mail to rgpd@absiskey.com.
<br>The Publisher will however take the precaution of verifying the identity of the applicant by means of a signed identity document before granting him access to his personal data.
<br>
<br><p style="text-decoration: underline;"><b>Article 12: Right of rectification</b></p>
Each User has, in accordance with the legislation in force, the right to rectify personal data concerning him/her.
<br>This right allows personal data that is inaccurate, incomplete, ambiguous or out of date to be rectified, completed, updated, blocked or deleted.
<br>The User may exercise this right by sending an e-mail to rgpd@absiskey.com.
<br>The Publisher will, however, take the precaution of verifying the identity of the applicant by means of a signed identity document before proceeding with the modification of his/her personal data.
<br>
<br><p style="text-decoration: underline;"><b>Article 13 - Right of deletion</b></p>
Each User has, in accordance with the legislation in force, the right to delete personal data concerning him/her.
<br>This right allows personal data to be deleted.
<br>The User may exercise this right by sending an e-mail to rgpd@absiskey.com
<br>The Editor will however take the precaution of verifying the identity of the applicant via a signed identity document before proceeding to delete his personal data before the end of the retention period (see article "Retention of collected personal data").
<br>
<br><p style="text-decoration: underline;"><b>Article 14 - Right to object on legitimate grounds</b></p>
The Publisher will study any request to oppose the use of personal data in accordance with the principles set out in the previous articles.
<br>The User may exercise this right by sending an e-mail to rgpd@absiskey.com
<br>However, the Publisher will take the precaution of verifying the identity of the applicant by means of a signed identity document before proceeding with the opposition.
<br>
<br><p style="text-decoration: underline;"><b>Article 15 - Right to limit processing</b></p>
Each user has, in accordance with the legislation in force, the right to limit the processing of personal data concerning him/her, i.e. to freeze the data at a precise moment in time, particularly in the event of a dispute.
<br>The User may exercise this right by sending an e-mail to rgpd@absiskey.com
<br>The Publisher will however take the precaution of verifying the identity of the applicant by means of a signed identity document beforehand.
<br>
<br><p style="text-decoration: underline;"><b>Article 16 - Cookies</b></p>
Browsing on the Site is likely to cause the installation of cookie(s) on the User's computer.
<br>A cookie is a small file, which does not allow the identification of the user, but which records information relating to the navigation of a computer on a site. The data thus obtained is intended to facilitate subsequent navigation on the site, and is also intended to allow various measures of frequentation and audience.
<br>The cookies present on the Site come from google analytics. They do not collect any personal data from the User. These cookies record the traffic on the Site. The IP address, which is anonymised, is not personal data in this case.
<br>
<br><p style="text-decoration: underline;"><b>Article 17 - Setting of cookies</b></p>
Refusing to install a cookie may make it impossible to access certain services.
<br>However, the User can also configure his computer in the following way, to refuse the installation of cookies
<br>• Under Brave: Click on the menu icon (symbolised by 3 horizontal lines) at the top right of the browser. Select Settings. In the "protection" section, you can block cookies.
<br>• Under Chrome: Click on the menu icon (symbolised by three horizontal lines) at the top right of the browser. Select Settings. Click on Show advanced settings. In the "Privacy" section, click on preferences. In the 'Privacy' tab, you can block cookies.
<br>• In Firefox: At the top of the browser window, click on the Firefox button, then go to the Options tab. Click on the Privacy tab. Set the Retention Rules to: use custom settings for history. Finally uncheck it to disable cookies.
<br>• In Internet Explorer: Tools tab (cog-shaped icon in the upper right-hand corner) / Internet options. Click on Confidentiality and choose Block all cookies. Validate with Ok.
<br>• Under Safari: Click on the menu icon (symbolised by a cog) at the top right of the browser. Select Settings. Click on Show advanced settings. In the "Privacy" section, click on "Content Settings". In the "Cookies" section, you can block cookies.
<br>
<br><p style="text-decoration: underline;"><b>Article 18 - Social networks</b></p>
The Publisher's website uses plug-ins from the social networks Facebook, Linkedin, Twitter, You Tube (plug-in = extension that is added to your application in order to provide new functionalities. A plug-in cannot work alone and is often created by users).
<br>Social plug-ins are identical to the logos of the social networking sites used.
<br>If the User calls up a web page on the Publisher's site containing these social plugins, a direct connection is established with the servers of this social network. The image that the User sees of the plugin and the underlying functions are then directly transmitted to the User's browser which integrates them.
<br>The Publisher therefore draws the User's attention to the fact that the content and volume of the data collected and transmitted directly to this network via the social plugin, as well as the duration of storage and the purpose of use, are determined exclusively by this provider.
<br>The User can find further information in the data protection notes of this provider:
<br>• Facebook <a href="https://www.facebook.com/about/privacy/">https://wwwfacebook.com/about/privacy/</a>
<br>• LinkedIn <a href="https://www.linkedin.com/legal/privacy-policy">https://www.linkedin.com/legal/privacy-policy</a>
<br>• Twitter <a href="https://help.twitter.com/en/rules-and-policies/update-privacy-policy">https://help.twitter.com/en/rules-and-policies/update-privacy-policy</a>
<br>• You Tube <a href="https://www.youtube.com/howyoutubeworks/user-settings/privacy/">https://www.youtube.com/howyoutubeworks/user-settings/privacy/</a>
<br>• Vimeo <a href="https://vimeo.com/privacy">https://vimeo.com/privacy</a>
<br>
<br><p style="text-decoration: underline;"><b>Article 19 - Right to lodge a complaint with a supervisory authority</b></p>
The Publisher's intention is to find an amicable solution to all disputes that may arise.
<br>Nevertheless, each User has the right to lodge a complaint with the supervisory authority. In France, the competent supervisory authority for the protection of personal data is the Commission Nationale de l'Informatique et des Libertés (CNIL), whose website is available at this address: <a href="https://www.cnil.fr">https://www.cnil.fr</a>.
</div>
</div>
</div>
</div>
</footer>
<div id="real_twitter_display">
<div id="tbox1" style="left: -302px; top: 100px; z-index: 10000; height: 310px;">
<div id="tbox2" style="width:292px;height:310px;">
<a class="open" id="fblink" href="#"></a><img style="right:-50px;" src="img/website/twitter-icon.png" alt="">
<a class="twitter-timeline" data-lang="en" data-width="280" data-height="300" href="https://twitter.com/https://twitter.com/epic_crown_2">Tweets by https://twitter.com/epic_crown_2</a> <script async src="//platform.twitter.com/widgets.js" charset="utf-8"></script>
</div>
</div>
</div>
<div id="real_twitter_display3">
<div id="lbox1" style="left: -302px; top: 300px; z-index: 10000; height: 310px;">
<div id="lbox2" style="width:292px;height:310px;">
<a class="open" id="llink" href="https://www.linkedin.com/in/epiccrown2" target="_blank"><img style="right:-56px;width:55px;" src="img/website/linkedin_2.png" alt=""></a>
</div>
</div>
</div>
<!-- pie chart-->
<script>
var correctCaptcha = function(response) {
// If the checkbox is checked, display the output text
$('#btn-contact').prop("disabled",false);
}
function recaptchaExpired(){
//alert("Your Recaptcha has expired, please verify it again !");
$('#btn-contact').prop("disabled",true);
}
function confirmMail() {
document.getElementById('div_ok').innerHTML = 'The mail has been sent successfully.';
document.getElementById('div_ok').style.color='#fff';
document.getElementById('div_ok').style.backgroundColor='#46a9e0';
document.getElementById('div_ok').style.display='';
setTimeout(function(){ document.getElementById('div_ok').style.display='none';},3000);
document.getElementById('Name').value = "";
document.getElementById('Email').value = "";
document.getElementById('Subject').value = "";
document.getElementById('Message').value = "";
document.getElementById('captcha_field').value = "";
}
function mailFail() {
document.getElementById('div_ok').innerHTML = 'A problem occured. The mail has not been sent.';
document.getElementById('div_ok').style.color='#000';
document.getElementById('div_ok').style.backgroundColor='yellow';
document.getElementById('div_ok').style.display='';
}
function captchaFail() {
document.getElementById('div_ok').innerHTML = 'That CAPTCHA was incorrect. The mail has not been sent.';
document.getElementById('div_ok').style.color='#000';
document.getElementById('div_ok').style.backgroundColor='yellow';
document.getElementById('div_ok').style.display='';
}
function validText(tfid,divid)
{
document.getElementById(tfid).style.backgroundColor='#eee';
mytext = document.getElementById(tfid).value;
if(mytext.length<1 || mytext == ' Login' || mytext == ' Password')
{
document.getElementById(tfid).style.backgroundColor='yellow';
document.getElementById(tfid).focus();
document.getElementById(divid).innerHTML = 'This field is required. Please enter a value.';
document.getElementById(divid).style.color='#000';
document.getElementById(divid).style.backgroundColor='yellow';
document.getElementById(divid).style.display='';
return false;
}
else
{
return true;
}
}
function validSpam(tfid)
{
document.getElementById(tfid).style.backgroundColor='#eee';
mytext = document.getElementById(tfid).value;//alert(mytext);
var pos = mytext.indexOf("http://");//alert(pos);
var pos2 = mytext.indexOf("https://");//alert(pos);
var pos3 = mytext.indexOf("http");//alert(pos);
if(pos>=0||pos2>=0||pos3>=0)
{
document.getElementById(tfid).style.backgroundColor='yellow';
document.getElementById(tfid).focus();
document.getElementById('div_ok').innerHTML = 'Incorrect input.';
document.getElementById('div_ok').style.color='#000';
document.getElementById('div_ok').style.backgroundColor='yellow';
document.getElementById('div_ok').style.display='';
return false;
}
else
{
return true;
}
}
function validCB(cbid)
{
if(document.getElementById(cbid).checked)
{
return true;
}
else
{
document.getElementById('div_ok').innerHTML = "Please accept the general conditions of use.";
document.getElementById('div_ok').style.color='#000';
document.getElementById('div_ok').style.backgroundColor='yellow';
document.getElementById('div_ok').style.display='';
return false;
}
}
function showMember()
{
var nbmember = 0;
if($('#showmoremembers').text()=='Show more members') nblimit = 9;
else nblimit = 1000;
console.log(nblimit);
//get partner selected
var listepartner = '';
var tabpartner = new Array();
$(".spanprojectblue").each(function (index) {
//alert($(this).attr("id"));
id = $(this).attr("id");
if (id.indexOf("partner") >= 0) {
partner = 'p'+id.substring(8)+'p';
//alert("trouve ville "+ville);
if(listepartner.length>0) listepartner+=","+partner;
else listepartner = partner;
tabpartner[tabpartner.length] = partner;
}
} );
//console.log(listepartner);
//console.log(tabpartner.length);
//foreach member
$( ".article-member" ).each(function( index ) {
//console.log( $( this ).attr("class") );
if(tabpartner.length>0){
affiche = 'n';
//check partner
for(i=0;i<tabpartner.length;i++)
{
partner = tabpartner[i];
if($( this ).attr("class").indexOf(partner)>=0) {
nbmember = nbmember+1;
if(nbmember<nblimit) affiche = 'y';
else affiche='n';
}
}
}
else {
nbmember = nbmember+1;
if(nbmember<nblimit) affiche='y';
else affiche='n';
}
if(affiche=='y') $(this).show();
else $(this).hide();
});
}
function receiveMessage(event)
{
// Faisons-nous confiance à l'expéditeur de ce message ? (il pourrait être
// différent de la fenêtre que nous avons ouverte au départ, par exemple).
//if (event.origin !== "http://example.org")
// return;
if(event.data=="captcha") captchaFail();
else if(event.data=="ok") confirmMail();
else if(event.data=="pbmail") mailFail();
}
window.addEventListener("message", receiveMessage, false);
$(document).ready(function() {
$('#showmoremembers').click(function () {
console.log('showmoremembers');
console.log($('#showmoremembers').text());
if($('#showmoremembers').text()=='Show more members')
{
$(this).text('Hide more members');
showMember();
}
else
{
//gotonewsheader
//var tag = $('#members');
//$('html,body').animate({scrollTop: tag.offset().top - 60},'slow');
$(this).text('Show more members');
showMember();
}
});
$('#alegal').click(function () {
if ($('#divlegal').css('display') == 'none') {
$('#divcharte').hide();
$('#divlegal').show();
$("html, body").animate({ scrollTop: $(document).height() }, 1000);
}
else $('#divlegal').hide();
});
$('#alegal2').click(function () {
if ($('#divlegal').css('display') == 'none') {
$('#divcharte').hide();
$('#divlegal').show();
$("html, body").animate({ scrollTop: $(document).height() }, 1000);
}
else $('#divlegal').hide();
});
$('#acharte').click(function () {
if ($('#divcharte').css('display') == 'none') {
$('#divlegal').hide();
$('#divcharte').show();
$("html, body").animate({ scrollTop: $(document).height() - 2100 }, 1000);
}
else $('#divcharte').hide();
});
imageUrl = 'upload/epiccrown2/website/cover.jpg';
$('#project .bg-photo').css('background-image', 'url('+imageUrl+')');
/*background-repeat: no-repeat;
background-attachment: fixed;
background-position: center; */
imageUrl = 'upload/epiccrown2/website/inter.jpg';
$('#picture .bg-photo').css('background-image', 'url('+imageUrl+')');
imageUrl = 'upload/epiccrown2/website/news.jpg';
$('#news .bg-photo').css('background-image', 'url('+imageUrl+')');
imageUrl = 'upload/epiccrown2/website/docs.jpg';
$('#documents .bg-photo').css('background-image', 'url('+imageUrl+')');
//Get colors from CSS
var a = $('<a />').css('display', 'none');
$('body').append(a);
var color_1 = a.addClass('chart-caption1').css('background-color');
a.removeClass('chart-caption1');
var color_2 = a.addClass('chart-caption2').css('background-color');
a.removeClass('chart-caption1');
var color_3 = a.addClass('chart-caption3').css('background-color');
a.remove();
var color_4 = a.addClass('chart-caption4').css('background-color');
a.remove();
$('.bxslidervideo').bxSlider({
video: true,
useCSS: false
});
$('.spanproject').click(function () {
if($(this).attr('class')=='spanproject') {
$('.spanprojectblue').removeClass("spanprojectblue").addClass("spanproject");
$(this).removeClass("spanproject").addClass("spanprojectblue");
showMember();
}
else {
$(this).removeClass("spanprojectblue").addClass("spanproject");
showMember();
}
});
$('.spanprojectblue').click(function () {
if($(this).attr('class')=='spanproject') {
$(this).removeClass("spanproject").addClass("spanprojectblue");
showMember();
}
else {
$(this).removeClass("spanprojectblue").addClass("spanproject");
showMember();
}
});
$('#myModal').on('show.bs.modal', function (event) {
var button = $(event.relatedTarget) // Button that triggered the modal
var newstitle = button.data('title') // Extract info from data-* attributes
var newstext = button.data('text') // Extract info from data-* attributes
console.log(button);
// Update the modal's content. We'll use jQuery here, but you could use a data binding library or other methods instead.
var modal = $(this)
modal.find('.modal-title').text(newstitle)
modal.find('.modal-body').html(newstext)
})
$('#btn-contact').click(function () {
if(validText('Name','div_ok')){
if(validText('Email','div_ok')){
if(validText('Subject','div_ok')){
if(validSpam('Message')){if(validCB('checkBox')){
$('#mailform').submit();
}}
}
}
}
});
$('#btn-login').click(function () {
if(validText('login','div_loginok')){
if(validText('password','div_loginok')){
$('#loginform').submit();
}
}
});
//twitter
jQuery(function (){
jQuery("#tbox1").hover(function(){
jQuery('#tbox1').css('z-index',101009);
jQuery(this).stop(true,false).animate({left: 0}, 500); },
function(){
jQuery('#tbox1').css('z-index',10000);
jQuery("#tbox1").stop(true,false).animate({left: -302}, 500); });
});
//facebook
jQuery(function (){
jQuery("#fbox1").hover(function(){
jQuery('#fbox1').css('z-index',101009);
jQuery(this).stop(true,false).animate({left: 0}, 500); },
function(){
jQuery('#fbox1').css('z-index',10000);
jQuery("#fbox1").stop(true,false).animate({left: -302}, 500); });
});
});
</script>
<!-- Include the Google Maps API library - required for embedding maps -->
<!--script src="https://maps.googleapis.com/maps/api/js?sensor=false"></script-->
<script src="https://maps.googleapis.com/maps/api/js?key=AIzaSyDApou8O9k0YHipRKMG8iuxYIofxQepjs8"></script>
<script type="text/javascript" src="js/markerwithlabel_v2.js"></script>
<script type="text/javascript">
// The latitude and longitude of your business / place
var position = [44.19663246,8.02777004];
function showGoogleMaps() {
var latLng = new google.maps.LatLng(position[0], position[1]);
var mapOptions = {
zoom: 4, // initialize zoom level - the max value is 21
streetViewControl: false, // hide the yellow Street View pegman
scaleControl: false, // allow users to zoom the Google Map
scrollwheel: false,
mapTypeId: google.maps.MapTypeId.ROADMAP,
center: latLng
};
map = new google.maps.Map(document.getElementById('googlemaps'),
mapOptions);
marker3 = new MarkerWithLabel({
position: new google.maps.LatLng(45.7275497,4.8364772),
map: map,
draggable: false,
raiseOnDrag: false,
labelContent: 'FAB',
labelAnchor: new google.maps.Point(-13, 38),
labelClass: 'labels_maps2', // the CSS class for the label
labelInBackground: true
});
marker3 = new MarkerWithLabel({
position: new google.maps.LatLng(43.3096315,5.368839),
map: map,
draggable: false,
raiseOnDrag: false,
labelContent: 'IRD',
labelAnchor: new google.maps.Point(-13, 38),
labelClass: 'labels_maps2', // the CSS class for the label
labelInBackground: true
});
marker3 = new MarkerWithLabel({
position: new google.maps.LatLng(40.3821578,-3.697365),
map: map,
draggable: false,
raiseOnDrag: false,
labelContent: 'IMAS12',
labelAnchor: new google.maps.Point(-13, 38),
labelClass: 'labels_maps2', // the CSS class for the label
labelInBackground: true
});
marker3 = new MarkerWithLabel({
position: new google.maps.LatLng(38.0170533,23.666029),
map: map,
draggable: false,
raiseOnDrag: false,
labelContent: 'HISS',
labelAnchor: new google.maps.Point(-13, 38),
labelClass: 'labels_maps2', // the CSS class for the label
labelInBackground: true
});
marker3 = new MarkerWithLabel({
position: new google.maps.LatLng(53.54677,9.96487),
map: map,
draggable: false,
raiseOnDrag: false,
labelContent: 'BNITM',
labelAnchor: new google.maps.Point(-13, 38),
labelClass: 'labels_maps2', // the CSS class for the label
labelInBackground: true
});
}
window.addEventListener( 'load', showGoogleMaps);
// add class sticky to top-header
$(window).scroll(function() {
var scroll = $(window).scrollTop();
if (scroll >= 650) {
$(".vitamib-navbar-scroll").addClass("sticky");
} else {
$(".vitamib-navbar-scroll").removeClass("sticky");
}
});
// add class sticky to tabbar mobile partner
$(window).scroll(function() {
var scroll = $(window).scrollTop();
if (scroll >= 2200) {
$(".h2-mobile").addClass("sticky");
} else {
$(".h2-mobile").removeClass("sticky");
}
if (scroll >= 5400) {
$(".h2-mobile").removeClass("sticky");
}
});
/*slider thumbnails */
$('#myCarousel').carousel({
interval: 5000
});
$('#carousel-text').html($('#slide-content-0').html());
//Handles the carousel thumbnails
$('[id^=carousel-selector-]').click( function(){
var id = this.id.substr(this.id.lastIndexOf("-") + 1);
var id = parseInt(id);
$('#myCarousel').carousel(id);
});
// When the carousel slides, auto update the text
$('#myCarousel').on('slid.bs.carousel', function (e) {
var id = $('.item.active').data('slide-number');
$('#carousel-text').html($('#slide-content-'+id).html());
});
hashid = document.location.hash;
if(hashid.length>1)
{
//console.log(hashid);
if(hashid.indexOf('dissem') !== -1)
{
//alert('dissem');
$("#Dissem_collapse").attr('aria-expanded', true);
$("#Dissem_collapse").removeClass('collapsed');
$("#collapseDissem").addClass('in');
}
else if(hashid.indexOf('results') !== -1)
{
//alert('results');
$("#Results_collapse").attr('aria-expanded', true);
$("#Results_collapse").removeClass('collapsed');
$("#collapseResults").addClass('in');
}
else if(hashid.indexOf('exploitation') !== -1)
{
//alert('exploitation');
$("#Exploitation_collapse").attr('aria-expanded', true);
$("#Exploitation_collapse").removeClass('collapsed');
$("#collapseExploitation").addClass('in');
}
else if(hashid.indexOf('webinar') !== -1)
{
window.location.replace("https://teams.microsoft.com/registration/ug1lEQMUIUGbICkJ7tQoaQ,W_vt5MBPYUWyM1N4mQQKuA,Xtymn-5zP0KHIlbl5FR32w,r_avoA91jUCH4CbMGVWNyQ,kJppdvWsekK6sTRcJG1Z_Q,Nvu770-WukeNfuycHVeAsA?mode=read&tenantId=11650dba-1403-4121-9b20-2909eed42869");
//window.location.href = "http://stackoverflow.com";
}
else if(hashid.indexOf('news') !== -1)
{
$(function () {
mylink = hashid.replace('#', 'a_');
//console.log(mylink);
//$("#a_news_5").trigger( "click" );
$("#"+mylink).trigger( "click" );
//console.log("#a_news_5".dataset);
});
}
var tag = $(hashid);
$('html,body').animate({scrollTop: tag.offset().top - 60},'slow');
}
</script>
</body>
</html>
Sitemap
Кол-во: 0
XML-карта сайта для поисковиков
?
Sitemap.xml помогает поисковику быстрее находить и индексировать страницы. Особенно важен для крупных сайтов и новых страниц, на которые ещё нет входящих ссылок.
Robots.txt не содержит ссылку на карту сайта. Рекомендуется добавить карту сайта и указать ссылку на нее в robots.txt.
Внутренние ссылки
Не найдено
Ссылки на другие страницы своего сайта
?
Внутренние ссылки распределяют ссылочный вес между страницами и помогают поисковику обходить сайт. Пустые анкоры и ссылки на запрещённые robots.txt страницы — типичные ошибки.
Внутренних ссылок на странице 0 оптимально.
На странице присутствуют изображения 5.
Внешние ссылки
Кол-во: 14
Ссылки на сторонние сайты
?
Исходящие внешние ссылки передают часть ссылочного веса на чужие сайты. Ссылки на авторитетные ресурсы безопасны; ссылки на мусорные сайты могут навредить репутации страницы.
Внешних ссылок на странице 14 слишком много. Спрячьте лишние ссылки в тег noindex или атрибут rel='nofollow'!
Показать внешние ссылки
| Url | Анкор | Анализировать |
|---|---|---|
| imas12.es |
<p class="container-img">
<img class="img-responsive center-block" src="upload/epiccrown2/website/logo imas12 sin fondo blanco.png" alt="">
</p>
|
Анализировать url |
| sepsis.gr |
<p class="container-img">
<img class="img-responsive center-block" src="upload/epiccrown2/website/LOGO gr sepsis b.png" alt="">
</p>
|
Анализировать url |
| bnitm.de |
<p class="container-img">
<img class="img-responsive center-block" src="upload/epiccrown2/website/BNITM-LOGO-13-E.png" alt="">
</p>
|
Анализировать url |
| projectnetboard.com |
Project netboard
|
Анализировать url |
| projectnetboard.com |
www.projectnetboard.com
|
Анализировать url |
| absiskey.com |
www.absiskey.com
|
Анализировать url |
| facebook.com |
https://wwwfacebook.com/about/privacy/
|
|
| linkedin.com |
https://www.linkedin.com/legal/privacy-policy
|
Анализировать url |
| help.twitter.com |
https://help.twitter.com/en/rules-and-policies/update-privacy-policy
|
|
| youtube.com |
https://www.youtube.com/howyoutubeworks/user-settings/privacy/
|
Анализировать url |
| vimeo.com |
https://vimeo.com/privacy
|
Анализировать url |
| cnil.fr |
https://www.cnil.fr
|
Анализировать url |
| twitter.com |
Tweets by https://twitter.com/epic_crown_2
|
|
| linkedin.com |
<img style="right:-56px;width:55px;" src="img/website/linkedin_2.png" alt="">
|
Анализировать url |
Конкуренты Готовность: 0%
Конкуренты в Яндексе
Кол-во: 0
Топ сайтов-конкурентов в Яндексе
?
Сайты, чаще всего появляющиеся в ТОПе Яндекса по запросам из семантического ядра этой страницы.
Мы не нашли у вас конкурентов в Яндексе. Сайт или очень молодой или плохо продвигается.
Конкурентов в ТОП-10 Яндекса не нашлось.
Конкуренты в Google
Кол-во: 0
Топ сайтов-конкурентов в Google
?
Сайты, чаще всего появляющиеся в ТОПе Google по запросам из семантического ядра этой страницы.
Конкуренты в Google тоже не найдены. Займитесь продвижением сайта!
Конкурентов в ТОП-10 Google не нашлось.
ЗоЗПП: права потребителей Готовность: 100%
Нарушения
Не выявлены
Признаков дистанционной продажи товаров (интернет-магазина) не обнаружено — требования ЗоЗПП о раскрытии информации продавца к сайту не применяются. Нарушений нет.
ФЗ-149: рекомендательные технологии Готовность: 100%
Нарушения
Не выявлены
Рекомендательные блоки («с этим покупают», «похожие товары» и т.п.) на сайте не обнаружены — требования ст. 10.7 ФЗ-149 к сайту не применяются. Нарушений нет.
ФЗ-38: реклама Готовность: 100%
Нарушения
Не выявлены
Рекламных тематик с обязательными оговорками (медицина, БАД, кредиты и займы, новостройки) на сайте не обнаружено. Нарушений нет.
ФЗ-436: защита детей Готовность: 100%
Нарушения
Не выявлены
Признаков информационной продукции (новости, видео, книги, игры, курсы) не обнаружено — обязательная возрастная маркировка по ФЗ-436 сайту не требуется. Нарушений нет.
Вердикт
Таким сайт epic-crown-2.com видят поисковые системы. Процент оптимизации невысокий - 39%. Чтобы улучшить сайт и попасть в ТОП необходимо:
Постарайтесь исправить общие ошибки.
Исправьте ошибки в мета-тегах.
Исправьте ошибки индексации.
Поделитесь с друзьями: